<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Divers</journal-id><journal-id journal-id-type="iso-abbrev">Mol Divers</journal-id><journal-title-group><journal-title>Molecular Diversity</journal-title></journal-title-group><issn pub-type="ppub">1381-1991</issn><issn pub-type="epub">1573-501X</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38656598</article-id><article-id pub-id-type="pmc">PMC11785708</article-id>
<article-id pub-id-type="publisher-id">10830</article-id><article-id pub-id-type="doi">10.1007/s11030-024-10830-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Design and synthesis of new quinazolinone derivatives: investigation of antimicrobial and biofilm inhibition effects</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Hassan</surname><given-names>Rasha Mohamed</given-names></name><address><email>rashahassan_pharma@yahoo.ca</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yehia</surname><given-names>Heba</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>El-Behairy</surname><given-names>Mohammed F.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>El-Azzouny</surname><given-names>Aida Abdel-Sattar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Aboul-Enein</surname><given-names>Mohamed Nabil</given-names></name><address><email>mnaboulenein@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02n85j827</institution-id><institution-id institution-id-type="GRID">grid.419725.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 8157</institution-id><institution>Medicinal and Pharmaceutical Chemistry Department, Pharmaceutical and Drug Industries Research Institute, </institution><institution>National Research Centre (ID: 60014618), </institution></institution-wrap>P.O. 12622, Dokki, Giza, Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02n85j827</institution-id><institution-id institution-id-type="GRID">grid.419725.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2151 8157</institution-id><institution>Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, </institution><institution>National Research Centre (ID: 60014618), </institution></institution-wrap>P.O. 12622, Dokki, Giza, Egypt </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05p2q6194</institution-id><institution-id institution-id-type="GRID">grid.449877.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 4652 351X</institution-id><institution>Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, </institution><institution>University of Sadat City, </institution></institution-wrap>32897, Sadat City, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>4</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>29</volume><issue>1</issue><fpage>21</fpage><lpage>42</lpage><history><date date-type="received"><day>30</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>25</day><month>2</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">New quinazolin-4-ones <bold>9&#x02013;32</bold> were synthesized in an attempt to overcome the life-threatening antibiotic resistance phenomenon. The antimicrobial screening revealed that compounds <bold>9</bold>, <bold>15</bold>, <bold>16</bold>, <bold>18</bold>, <bold>19</bold>, <bold>20</bold> and <bold>29</bold> are the most broad spectrum antimicrobial agents in this study with safe profile on human cell lines. Additionally, compounds <bold>19</bold> and <bold>20</bold> inhibited biofilm formation in <italic>Pseudomonas aeruginosa</italic>, which is regulated by quorum sensing system, at sub-minimum inhibitory concentrations (sub-MICs) with IC<sub>50</sub> values 3.55 and 6.86&#x000a0;&#x000b5;M, respectively. By assessing other pseudomonal virulence factors suppression, it was found that compound <bold>20</bold> decreased cell surface hydrophobicity compromising bacterial cells adhesion, while both compounds <bold>19</bold> and <bold>20</bold> curtailed the exopolysaccharide production which constitutes the major component of the matrix binding biofilm components together. Also, at sub-MICs <italic>Pseudomonas</italic> cells twitching motility was impeded by compounds <bold>19</bold> and <bold>20</bold>, a trait which augments the cells pathogenicity and invasion potential. Molecular docking study was performed to further evaluate the binding mode of candidates <bold>19</bold> and <bold>20</bold> as inhibitors of <italic>P. aeruginosa</italic> quorum sensing transcriptional regulator PqsR<italic>.</italic> The achieved results demonstrate that both compounds bear promising potential for discovering new anti-biofilm and quorum quenching agents against <italic>Pseudomonas aeruginosa</italic> without triggering resistance mechanisms as the normal bacterial life cycle is not disturbed.</p><sec><title>Graphical abstract</title><p id="Par2">New 4-quinazolinones were synthesized and screened for their antimicrobial activity. Compounds <bold>19</bold> and <bold>20</bold> inhibited biofilm formation in <italic>Pseudomonas aeruginosa</italic> at sub- minimum inhibitory concentrations. Also, they decreased other virulence factors at low concentrations without affecting bacterial growth bacteria indicating their promising profile as anti-virulence agents that cause less bacterial resistance than the conventional antibiotics.</p><p id="Par3">
<graphic position="anchor" xlink:href="11030_2024_10830_Figa_HTML" id="MO1"/></p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11030-024-10830-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Quinazolinones</kwd><kwd>Antimicrobial</kwd><kwd>Biofilm inhibition</kwd><kwd><italic>Pseudomonas aeruginosa</italic></kwd></kwd-group><funding-group><award-group><funding-source><institution>National Research Centre Egypt</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">The tremendous increase in the microbial resistance to the marketed therapeutic agents is the driving motivation for the development of new drugs for the management of infectious diseases [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>] specially that they are often reported with cancer and cardiovascular diseases as the major causes of mortality and morbidity worldwide, while they bear the additional gravity of being communicable [<xref ref-type="bibr" rid="CR3">3</xref>]. Hence, their risk is not only restricted to the subjects in contact with contaminated environments but also keep spreading to further circles via direct or indirect transfer. In the war against bacterial resistance, it is not enough anymore to develop new antibiotics with a distinct mechanism of action, e.g.: disrupting synthesis of proteins, nucleic acid or cell wall, metabolic pathways interruption, cell membrane structure or performance disintegration [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Instead, one of the promising approaches is to target bacterial cells communication mechanism, commonly known as quorum sensing (QS) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. QS controls bacterial cells coordination through signal molecules called autoinducers which stimulate specific receptors and consequently, regulate several biochemical processes in bacteria via transcriptional signals. These processes are the ones that mainly govern pathogenesis and involve, but are not limited to, bacterial motility, expression of virulence factors, biofilm formation, and antibiotics resistance [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Accordingly, annihilation of quorum sensing network, with or without influencing bacterial growth, is per se an efficient strategy to disrupt cumulative production of virulence factors and debilitate the pathogenicity of bacteria [<xref ref-type="bibr" rid="CR9">9</xref>]. Interestingly, molecules which inhibit virulence factors and biofilm formation in bacteria, without affecting bacterial growth, are less likely to trigger resistance mechanisms in comparison to conventional antibiotics due to the absence of the selective pressure. This occurs as cells do not acquire induced resistance and do not pass down the relevant genetic material [<xref ref-type="bibr" rid="CR3">3</xref>]. Ideally, these agents should not interfere with bacterial and host metabolism or lead to any harmful side effects to be eligible for clinical application [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par5"><italic>Pseudomonas aeruginosa</italic> is classified as a Gram-negative infectious bacterium. It is one of the most opportunistic bacteria and is responsible for several human infections, especially in immunocompromised and elderly patients, e.g.: urinary tract, burn and implant infections as well as chronic otitis. <italic>P. aeruginosa</italic> infection is mostly accompanied with respiratory failure, decreased pulmonary function and high mortality rate within cystic fibrosis patients [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. The severity of <italic>P. aeruginosa</italic> infections is due to the metabolic adaptation of the bacteria which are supported via many virulence factors and enzymes including transcriptional regulators, proteases as well as lipopolysaccharides [<xref ref-type="bibr" rid="CR8">8</xref>]. In addition, <italic>P. aeruginosa</italic> possesses the capability of colonizing surfaces in the form of biofilm communities; a trait which decreases the effectiveness of antibiotics, shields bacterial cells against hosts&#x02019; immune systems in vivo, and leads to antibacterial resistance by means of potentiated horizontal transfer of acquired resistance genes, e.g.: antibiotic-modifying enzymes, specific efflux pumps, decreased cell penetration, etc. [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par6">The QS system in <italic>P. aeruginosa</italic> consists of three interlinked systems namely, <italic>las</italic>, <italic>rhl</italic> and <italic>pqs</italic>, which play an important role in bacterial pathogenicity. Each cascade comprises a transcriptional regulator protein namely; LasR, RhlR and PqsR, respectively [<xref ref-type="bibr" rid="CR13">13</xref>]. Both LasR and RhlR systems operate through diffusion of <italic>N</italic>-acyl homoserine lactone as signaling or inducing molecules, whereas the PqsR (also named MvfR) system utilizes two alkylquinolones as autoinducers (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR14">14</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>2-Alkyl-4-quinolone (AQ) molecules acting as autoinducers of pqs system in <italic>Pseudomonas aeruginosa</italic></p></caption><graphic xlink:href="11030_2024_10830_Fig1_HTML" id="MO2"/></fig></p><p id="Par7">Quinazolinones have enriched the medicinal chemistry library with a huge number of bioactive molecules which possess different biological activities such as analgesic [<xref ref-type="bibr" rid="CR15">15</xref>], anti-inflammatory [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], anti-hyperlipidemic [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>] and anticancer agents [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. Aiming to overcome the hazards of microbes that are resistant to the available antimicrobial agents, extensive studies have disclosed the promising antibacterial and antifungal properties of 4(3<italic>H</italic>)-quinazolinone derivatives [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>]. Following this track, various 4(3<italic>H</italic>)-quinazolinone Schiff&#x02019;s base hybrids, derived from hydrazine, as compounds <bold>I</bold>-<bold>III</bold> [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>] have been reported to display significant antimicrobial activities (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Examples of 4(3<italic>H</italic>)-quinazolinones hybrids having antimicrobial and anti-biofilm effect</p></caption><graphic xlink:href="11030_2024_10830_Fig2_HTML" id="MO3"/></fig></p><p id="Par8">Additionally, the 4(3<italic>H</italic>)-quinazolinones are considered as one of the major classes that suppress biofilm formation. In this vein, the pyrimidin-4-yl quinazolin-4(3H)-one conjugate I<bold>V</bold> could efficiently inhibit biofilm formation in methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) with IC<sub>50</sub>&#x02009;=&#x02009;20.7&#x000a0;&#x003bc;M [<xref ref-type="bibr" rid="CR29">29</xref>]. Furthermore, the quinazolinone derivatives as compound <bold>V</bold> have anti-biofilm activity against <italic>Candida albicans</italic> with IC<sub>50</sub> less than 30&#x000a0;&#x003bc;M [<xref ref-type="bibr" rid="CR30">30</xref>]. Moreover, the quinazolinone-based derivatives as compounds <bold>VI</bold> and <bold>VII</bold> are inhibitors of <italic>P. aeruginosa</italic> quorum sensing transcriptional regulator PqsR and accordingly, attenuate biofilm formation [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>] (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par9">On the other hand, pyrrolidine, piperidine and morpholine are valuable saturated secondary amines that found in many antibacterial drugs as clinafloxacin, nadifloxacin and linezolid (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Moreover, alicyclic amines have fostered the antimicrobial potency of chemically synthesized compounds [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Interestingly, one of the most common metabolic pathways of alicyclic amines is &#x003b1;-carbonyl formation leading to lactam structures [<xref ref-type="bibr" rid="CR35">35</xref>] which are well known pharmacophores in antibacterial agents.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Antibacterial drugs containing alicyclic amines</p></caption><graphic xlink:href="11030_2024_10830_Fig3_HTML" id="MO4"/></fig></p><p id="Par10">Diverse substituents at 2-position of quinazoline-4-ones have displayed interesting antibacterial activity as per compounds <bold>I-VII</bold> (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Also, secondary/alicyclic amines have contributed positively to the potency of many antibacterial candidates (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). In the same vein, imine bond (Schiff&#x02019;s base) has been utilized as a linker in many candidates that showed antibacterial potential (compounds <bold>I-III</bold>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Therefore, in the current work, it has been decided to design hybrid structures (<bold>9</bold>&#x02013;<bold>32</bold>) containing the aforementioned moieties that were endowed with antibacterial activity. Hence, quinazolin-4-one has been hybridized at position 2 with secondary/alicyclic amines while diverse hydrophobic groups at position 3 were linked via Schiff&#x02019;s base to afford compounds <bold>9</bold>&#x02013;<bold>32</bold> (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Assessing the effect of substituting different open chain <bold>9</bold>&#x02013;<bold>14</bold> or alicyclic secondary amines <bold>15</bold>&#x02013;<bold>32</bold> on their antimicrobial activity was also studied (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). It is worth mentioning that the designed compounds also share structural similarity with the quinolones autoinducers of the pqs system of <italic>P. aeruginosa.</italic> The design was thus realized with the objective of evaluating the most active compounds in inhibiting the <italic>P. aeruginosa</italic> biofilm formation and other virulence factors at sub-MICs and thus, fulfilling the hypothesis that the pathogenicity decline should not be followed by prompting antibiotic resistance mechanisms. Molecular docking study was carried out to determine the binding mode of candidates <bold>19</bold> and <bold>20</bold> as inhibitors of <italic>P. aeruginosa</italic> quorum sensing transcriptional regulator PqsR<italic>.</italic><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Rational design of our candidates <bold>9</bold>&#x02013;<bold>32</bold></p></caption><graphic xlink:href="11030_2024_10830_Fig4_HTML" id="MO5"/></fig></p></sec><sec id="Sec2"><title>Results and discussion</title><sec id="Sec3"><title>Chemistry</title><p id="Par11">The synthesis of compounds <bold>9&#x02013;32</bold> and their intermediates is depicted in Scheme <xref rid="Sch1" ref-type="fig">1</xref>. The key intermediates <bold>5a-d</bold> were prepared by two routes. The first one involves the amidation of the anthranilic acid ester <bold>2</bold> using 2-chloroacetylchloride following the classical triethylamine catalyzed amidation [<xref ref-type="bibr" rid="CR36">36</xref>] to obtain the amide derivative <bold>3</bold>. The latter was allowed to react with NaI to give the iodo derivative then two molar equivalent of the secondary aliphatic or alicyclic amines have been added to afford compounds <bold>4a, c</bold> and <bold>d</bold> [<xref ref-type="bibr" rid="CR37">37</xref>]. Unfortunately, compound <bold>4b</bold> was obtained in very low yield via this route. Cyclization of methyl anthranilate-<italic>N</italic>-amide to quinazolin-4-one derivatives is reported in presence of hydrazine hydrate under diverse catalytic conditions for example, 1-butyl-3-methylimidazolium tetrafluoroborate in water [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>], phosphorus trichloride in tetrahydrofuran [<xref ref-type="bibr" rid="CR40">40</xref>], triethylammonium acetate; in microwave irradiation [<xref ref-type="bibr" rid="CR41">41</xref>], barium hydroxide octahydrate, phosphorus trichloride in tetrahydrofuran [<xref ref-type="bibr" rid="CR42">42</xref>], ethanol under microwave irradiation [<xref ref-type="bibr" rid="CR40">40</xref>] and the most simple method was using butan-1-ol and heating [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Thus, compounds <bold>4a, c</bold> and <bold>d</bold> were cyclized to the key quinazolin-4-one derivatives <bold>5a, c</bold>, and <bold>d</bold> via reaction with hydrazine hydrate in n-butanol.<fig id="Sch1"><label>Scheme 1</label><caption><p>Synthesis of target compounds <bold>9&#x02013;32</bold> and key intermediates</p></caption><graphic xlink:href="11030_2024_10830_Sch1_HTML" id="MO6"/></fig></p><p id="Par12">Due to the unsatisfactory yield of preparation of intermediate <bold>4b</bold>, another route has been accomplished where the cyclization step was performed prior to the nucleophilic replacement of chloride with secondary amines. Hence, the anthranilic acid <italic>N</italic>-amide <bold>6</bold> was prepared from anthranilic acid (<bold>1</bold>) following the same procedure of preparing <bold>3</bold> from <bold>2</bold>. Cyclization of <bold>6</bold> to benzoxazine-4-one <bold>7</bold> was carried out using acetic anhydride as a dehydrating agent [<xref ref-type="bibr" rid="CR44">44</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. The quinazolin-4-one <bold>8</bold> was obtained via reaction of benzoxazine-4-one <bold>7</bold> with hydrazine hydrate, however the yield was unsatisfactory for this reaction (30%). Compound <bold>8</bold> was then converted to compound <bold>5a-d</bold> via nucleophilic substitution of chloride at position 2 with excess secondary aliphatic or alicyclic amines to avoid effect of strong base like potassium carbonate on the starting materials. Target compounds <bold>9&#x02013;32</bold> were then achieved using the well-established Schiff&#x02019;s base synthesis from reaction of primary amine and aldehyde under acidic conditions.</p><p id="Par13"><sup>1</sup>H-NMR of compounds <bold>9&#x02013;32</bold> demonstrated the disappearance of the NH<sub>2</sub> singlet of compounds <bold>5a-d</bold> at &#x003b4;<sub>H</sub> 3.5&#x02013;4.00&#x000a0;ppm and the presence of the characteristic imine proton at &#x003b4;<sub>H</sub> 8.50&#x02013;9.00&#x000a0;ppm. Also, the number of aromatic protons has been increased by a number equivalent to the aldehyde protons while the singlet for 2H of the methylene bridge still noticeable but shifted downfield from &#x003b4;<sub>H</sub> 3.00&#x02013;3.5 in 5a-d to &#x003b4;<sub>H</sub> 3.50&#x02013;4.00&#x000a0;ppm in <bold>9&#x02013;32</bold>. In <sup>13</sup>C-NMR, three characteristic signals have been observed &#x003b4;<sub>c</sub> 150&#x02013;170&#x000a0;ppm corresponding to the carbonyl and C=N of the imine and quinazoline ring.</p></sec></sec><sec id="Sec4"><title>In vitro studies</title><sec id="Sec5"><title>Antimicrobial evaluation</title><p id="Par14">The antimicrobial activity of the new quinazolinone derivatives <bold>9</bold>&#x02013;<bold>32</bold> was determined against three Gram-positive bacteria: <italic>Bacillus cereus</italic> (<italic>B. cereus</italic> ATCC 6629), <italic>Bacillus subtilis</italic> (<italic>B. subtilis</italic> ATCC 6633) and <italic>Staphylococcus aureus</italic> (<italic>S. aureus</italic> ATCC 6538) as well as two Gram-negative bacteria: <italic>Klebsiella pneumoniae</italic> (<italic>K. pneumoniae</italic> ATCC 13883) and <italic>Pseudomonas aeruginosa</italic> (<italic>P. aeruginosa</italic> ATCC 27953) in addition to the opportunistic fungus <italic>Candida albicans</italic> (<italic>C. albicans</italic> ATCC 10231) using agar well diffusion method. The antibacterial ciprofloxacin and antifungal fluconazole were used as reference drugs and the diameters of the inhibition zones (in mm) are illustrated in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The tested compounds showed variable antimicrobial activity according to the secondary amines substitution on the C-2 of the quinazolinone ring. Nearly all of the pyrrolidine derivatives <bold>15</bold>&#x02013;<bold>20</bold> exhibited broad spectrum antimicrobial potential against both Gram (&#x02009;+) and Gram (-) bacteria except the <italic>para-</italic>tolyl derivative <bold>17</bold> that only showed antibacterial activity against the Gram (-) pathogen <italic>P. aeruginosa.</italic> Also, within the same group, compounds <bold>15</bold>, <bold>16</bold> and <bold>18</bold> displayed promising antifungal effect against the opportunistic yeast <italic>C. albicans</italic>. In the diethylamino series <bold>9</bold>&#x02013;<bold>14,</bold> only the unsubstituted phenyl derivative <bold>9</bold> exhibited antibacterial effect against both Gram (&#x02009;+) and Gram (-) bacteria but it lacked antifungal activity. Meanwhile, the trimethoxy phenyl derivative <bold>13</bold> had antifungal effect but it was selective towards Gram (-) bacteria rather than Gram (&#x02009;+) ones. Interestingly, the Gram (&#x02009;+)<italic>S. aureus</italic> was resistant to all the members of the diethylamino series <bold>9</bold>&#x02013;<bold>14</bold>. Regarding the piperidine analogues <bold>21</bold>&#x02013;<bold>26</bold>, most of the derivatives displayed antibacterial effect towards the Gram (-) <italic>K. pneumoniae</italic> except the <italic>para</italic>-chloro phenyl and <italic>para-</italic>tolyl derivatives <bold>22</bold> and <bold>23</bold>. In this group, both the unsubstituted phenyl derivative <bold>21</bold> and the <italic>para</italic>-nitro phenyl congener <bold>26</bold> affected the growth of Gram (&#x02009;+) and Gram (-) bacteria. Meanwhile, the mono methoxy phenyl and trimethoxy phenyl derivatives <bold>24</bold> and <bold>25</bold> were active towards the two examined Gram (-) bacteria <italic>K. pneumoniae</italic> and <italic>P. aeruginosa</italic> rather than Gram (&#x02009;+) bacteria. In this series, only the <italic>para-</italic>tolyl derivative <bold>23</bold> showed antifungal activity against <italic>C. albicans.</italic> Similar to the diethylamino series, the piperidine derivatives did not show antibacterial effect against <italic>S. aureus.</italic> Concerning the morpholine analogues <bold>27</bold>&#x02013;<bold>32</bold>, the <italic>para-</italic>tolyl derivative <bold>29</bold> revealed the broadest spectrum of activity within this series. However, complete loss of activity was observed upon introducing the trimethoxy phenyl moiety in compound <bold>31</bold>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Antimicrobial activity of compounds <bold>9</bold>&#x02013;<bold>32</bold> expressed as diameters of inhibition zone (mm)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Compound</th><th align="left" colspan="3">Gram positive bacteria</th><th align="left" colspan="2">Gram negative bacteria</th><th align="left">Fungi</th></tr><tr><th align="left">Number</th><th align="left"><italic>S. aureus</italic> ATCC 6538</th><th align="left"><italic>B. subtilis</italic> ATCC 6633</th><th align="left"><italic>B. cereus</italic> ATCC 6629</th><th align="left"><italic>K. pneumoniae</italic> ATCC 13883</th><th align="left"><italic>P. aeruginosa</italic> ATCC 27953</th><th align="left"><italic>C. albicans</italic> ATCC 10231</th></tr></thead><tbody><tr><td align="left"><bold>9</bold></td><td align="left">&#x02013;</td><td align="left">15&#x02009;&#x000b1;&#x02009;0.25</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.09</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.17</td><td align="left">21&#x02009;&#x000b1;&#x02009;0.36</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>10</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">15&#x02009;&#x000b1;&#x02009;0.15</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>11</bold></td><td align="left">&#x02013;</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.16</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>12</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">18&#x02009;&#x000b1;&#x02009;0.27</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>13</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.07</td><td align="left">20&#x02009;&#x000b1;&#x02009;0.18</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.28</td></tr><tr><td align="left"><bold>14</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.37</td></tr><tr><td align="left"><bold>15</bold></td><td align="left">12&#x02009;&#x000b1;&#x02009;0.26</td><td align="left">10&#x02009;&#x000b1;&#x02009;0.33</td><td align="left">&#x02013;</td><td align="left">13&#x02009;&#x000b1;&#x02009;0.41</td><td align="left">&#x02013;</td><td align="left">11&#x02009;&#x000b1;&#x02009;0.11</td></tr><tr><td align="left"><bold>16</bold></td><td align="left">12&#x02009;&#x000b1;&#x02009;0.08</td><td align="left">&#x02013;</td><td align="left">13&#x02009;&#x000b1;&#x02009;0.14</td><td align="left">&#x02013;</td><td align="left">17&#x02009;&#x000b1;&#x02009;0.26</td><td align="left">13&#x02009;&#x000b1;&#x02009;0.29</td></tr><tr><td align="left"><bold>17</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">16&#x02009;&#x000b1;&#x02009;0.22</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>18</bold></td><td align="left">14&#x02009;&#x000b1;&#x02009;0.21</td><td align="left">16&#x02009;&#x000b1;&#x02009;0.31</td><td align="left">17&#x02009;&#x000b1;&#x02009;0.30</td><td align="left">18&#x02009;&#x000b1;&#x02009;0.20</td><td align="left">&#x02013;</td><td align="left">13&#x02009;&#x000b1;&#x02009;0.14</td></tr><tr><td align="left"><bold>19</bold></td><td align="left">&#x02013;</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.31</td><td align="left">17&#x02009;&#x000b1;&#x02009;0.22</td><td align="left">18&#x02009;&#x000b1;&#x02009;0.24</td><td align="left">16&#x02009;&#x000b1;&#x02009;0.18</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>20</bold></td><td align="left">13&#x02009;&#x000b1;&#x02009;0.11</td><td align="left">10&#x02009;&#x000b1;&#x02009;0.12</td><td align="left">16&#x02009;&#x000b1;&#x02009;0.07</td><td align="left">16&#x02009;&#x000b1;&#x02009;0.09</td><td align="left">21&#x02009;&#x000b1;&#x02009;0.17</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>21</bold></td><td align="left">&#x02013;</td><td align="left">17&#x02009;&#x000b1;&#x02009;0.14</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.16</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.15</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>22</bold></td><td align="left">&#x02013;</td><td align="left">10&#x02009;&#x000b1;&#x02009;0.07</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>23</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">11&#x02009;&#x000b1;&#x02009;0.13</td></tr><tr><td align="left"><bold>24</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.14</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.21</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>25</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.17</td><td align="left">21&#x02009;&#x000b1;&#x02009;0.17</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>26</bold></td><td align="left">&#x02013;</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.11</td><td align="left">&#x02013;</td><td align="left">11&#x02009;&#x000b1;&#x02009;0.07</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>27</bold></td><td align="left">&#x02013;</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.15</td><td align="left">&#x02013;</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.16</td><td align="left">&#x02013;</td><td align="left">13&#x02009;&#x000b1;&#x02009;0.09</td></tr><tr><td align="left"><bold>28</bold></td><td align="left">&#x02013;</td><td align="left">12&#x02009;&#x000b1;&#x02009;0.20</td><td align="left">&#x02013;</td><td align="left">16&#x02009;&#x000b1;&#x02009;0.18</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>29</bold></td><td align="left">&#x02013;</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.06</td><td align="left">&#x02013;</td><td align="left">20&#x02009;&#x000b1;&#x02009;0.15</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.16</td><td align="left">13&#x02009;&#x000b1;&#x02009;0.07</td></tr><tr><td align="left"><bold>30</bold></td><td align="left">12&#x02009;&#x000b1;&#x02009;0.12</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.15</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>31</bold></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>32</bold></td><td align="left">&#x02013;</td><td align="left">14&#x02009;&#x000b1;&#x02009;0.27</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">18&#x02009;&#x000b1;&#x02009;0.09</td><td align="left">&#x02013;</td></tr><tr><td align="left">Ciprofloxacin</td><td align="left">23&#x02009;&#x000b1;&#x02009;0.15</td><td align="left">33&#x02009;&#x000b1;&#x02009;0.20</td><td align="left">29&#x02009;&#x000b1;&#x02009;0.18</td><td align="left">26&#x02009;&#x000b1;&#x02009;0.17</td><td align="left">35&#x02009;&#x000b1;&#x02009;0.28</td><td align="left">&#x02013;</td></tr><tr><td align="left">Fluconazole</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">20&#x02009;&#x000b1;&#x02009;0.18</td></tr></tbody></table></table-wrap></p><p id="Par15">Concurrently, all the tested compounds displayed poor antifungal activity against <italic>C. albicans</italic> where the pyrrolidine and morpholine derivatives <bold>15</bold> and <bold>29</bold> inhibited its growth recording MIC=5&#x000a0;mg/ml.</p></sec><sec id="Sec6"><title>Structure activity relationship</title><p id="Par16">Based on the preliminary antibacterial assay, compounds that displayed wide spectrum antimicrobial activity were subjected to minimum inhibitory concentration (MIC) determination (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). It was found that the pyrrolidine derivative <bold>20,</bold> substituted with 4-nitro phenyl group, was the most active compound on most of the tested bacteria.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>MIC values (mg/ml) of broad spectrum compounds</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Compound number</th><th align="left"><italic>S. aureus</italic> ATCC 6538</th><th align="left"><italic>B. subtilis</italic> ATCC 6633</th><th align="left"><italic>B. cereus</italic> ATCC 6629</th><th align="left"><italic>K. pneumoniae</italic> ATCC 13883</th><th align="left"><italic>P. aeruginosa</italic> ATCC 27953</th><th align="left"><italic>C. albicans</italic> ATCC 10231</th></tr></thead><tbody><tr><td align="left"><bold>9</bold></td><td align="left">&#x02013;</td><td align="left">2&#x02009;&#x000b1;&#x02009;0</td><td align="left">1&#x02009;&#x000b1;&#x02009;0</td><td align="left">1.5&#x02009;&#x000b1;&#x02009;0.06</td><td align="left">2&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>15</bold></td><td align="left">2&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">2&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">&#x02013;</td><td align="left">2&#x02009;&#x000b1;&#x02009;0</td><td align="left">&#x02013;</td><td align="left">5&#x02009;&#x000b1;&#x02009;0.29</td></tr><tr><td align="left"><bold>16</bold></td><td align="left">0.5&#x02009;&#x000b1;&#x02009;0</td><td align="left">&#x02013;</td><td align="left">2&#x02009;&#x000b1;&#x02009;0.14</td><td align="left">&#x02013;</td><td align="left">1.5&#x02009;&#x000b1;&#x02009;0</td><td align="left">10&#x02009;&#x000b1;&#x02009;0.5</td></tr><tr><td align="left"><bold>18</bold></td><td align="left">2.5&#x02009;&#x000b1;&#x02009;0</td><td align="left">1.5&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">2.5&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">2&#x02009;&#x000b1;&#x02009;0</td><td align="left">&#x02013;</td><td align="left">10&#x02009;&#x000b1;&#x02009;0.29</td></tr><tr><td align="left"><bold>19</bold></td><td align="left">&#x02013;</td><td align="left">1&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">10&#x02009;&#x000b1;&#x02009;0.5</td><td align="left">1&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">0.15&#x02009;&#x000b1;&#x02009;0.06</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>20</bold></td><td align="left">15&#x02009;&#x000b1;&#x02009;0.5</td><td align="left">0.5&#x02009;&#x000b1;&#x02009;0</td><td align="left">0.25&#x02009;&#x000b1;&#x02009;0</td><td align="left">0.5&#x02009;&#x000b1;&#x02009;0.29</td><td align="left">0.25&#x02009;&#x000b1;&#x02009;0.14</td><td align="left">&#x02013;</td></tr><tr><td align="left"><bold>29</bold></td><td align="left">&#x02013;</td><td align="left">0.5&#x02009;&#x000b1;&#x02009;0.06</td><td align="left">&#x02013;</td><td align="left">2.5&#x02009;&#x000b1;&#x02009;0.5</td><td align="left">1.5&#x02009;&#x000b1;&#x02009;0</td><td align="left">5&#x02009;&#x000b1;&#x02009;0.29</td></tr></tbody></table></table-wrap></p><p id="Par17">Analysis of the obtained results revealed that the pyrrolidine derivative <bold>16</bold> bearing <italic>para</italic>-chloro phenyl moiety was the most active compound against <italic>S. aureus</italic> with MIC=0.5&#x000a0;mg/ml. The antibacterial effect against the same organism decreased 4 and fivefold in the unsubstituted and <italic>para</italic>-methoxy phenyl congeners <bold>15</bold> and <bold>18</bold>, respectively. Also, the activity dropped severely (up to 30 fold) in presence of the strong electron withdrawing group (-NO<sub>2</sub>) in compound <bold>20</bold>. On the contrary, compound <bold>20</bold> as well as the morpholine analogue, that bears <italic>para-</italic>tolyl moiety, <bold>29</bold> are the most active against <italic>B. subtilis</italic> with equal MIC=0.5&#x000a0;mg/ml. Meanwhile, omitting the substitution on the phenyl ring in compound <bold>15</bold> or introducing electron donating group (-OCH<sub>3</sub>), in compounds <bold>18</bold> and <bold>19</bold>, led to a decline in the activity towards <italic>B. subtilis</italic> by 4, 3 and twofold, respectively. Regarding the other <italic>Bacillus</italic> species, <italic>B. cereus</italic>, compound <bold>20</bold> also possessed the highest activity with MIC=0.25&#x000a0;mg/ml. Within the pyrrolidine series, the inhibitory activity towards the previous pathogen declined by replacing the nitro group with moderate electron withdrawing group (-Cl) as in compound <bold>16</bold> or electron donating group (-OCH<sub>3</sub>) as in compound <bold>18</bold> by 8 and tenfold, respectively, as compared to compound <bold>20</bold>. It was observed that the trimethoxy phenyl derivative <bold>19</bold> was less potent against <italic>B. cereus</italic> than its mono methoxy phenyl analogue by fourfold. In addition, compound <bold>9,</bold> which bears diethylamino moiety at C-2 of the quinazolinone ring, antagonized the growth of this bacterium with MIC=1&#x000a0;mg/ml.</p><p id="Par18">With respect to Gram (-) bacteria, the pyrrolidine derivative bearing nitro group (compound <bold>20)</bold> was also the most powerful one against <italic>K. pneumoniae</italic> with MIC=0.5&#x000a0;mg/ml. The activity thereof decreased fourfold by removing the substitution on phenyl moiety, as in compound <bold>15</bold>, and in presence of electron donating group (-OCH<sub>3</sub>), as in compound <bold>18</bold>. Interestingly, the presence of trimethoxy substitution on the phenyl ring (compound <bold>19</bold>) enhanced the activity against <italic>K. pneumoniae</italic> by two fold compared to the mono methoxy derivative compound <bold>18</bold>. Compound <bold>29</bold> which is substituted at C-2 of quinazolinone with morpholine ring and possesses <italic>para-</italic>tolyl moiety as a component of Schiff&#x02019;s base was the least potent member towards <italic>K. pneumoniae</italic> (MIC=2.5&#x000a0;mg/ml). Concerning <italic>P. aeruginosa</italic>, it was found that the pyrrolidine derivative possessing trimethoxy phenyl group <bold>19</bold> displayed the best MIC=0.15&#x000a0;mg/ml among all the tested compounds. The <italic>p</italic>- nitro phenyl congener <bold>20</bold> was slightly less active than its trimethoxy counterpart<italic>.</italic> Meanwhile, the antibacterial activity of compound <bold>19</bold> dropped tenfold upon replacing the trimethoxy electron donating group by electron withdrawing group (-Cl) in compound <bold>16</bold>. The least active compound against <italic>P. aeruginosa</italic> was the diethylamino derivative <bold>9</bold> with MIC=2&#x000a0;mg/ml.</p></sec><sec id="Sec7"><title>Cell viability assay</title><p id="Par19">Cell viability testing at 5&#x000a0;mg/ml was carried out by colorimetric MTT assay on human normal cell line BJ1 (skin fibroblasts) to investigate the toxicity of the most broad spectrum derivatives <bold>9</bold>, <bold>15</bold>, <bold>16</bold>, <bold>18</bold>, <bold>19</bold>, <bold>20</bold> and <bold>29</bold> (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The viability of the cells treated with the aforementioned derivatives was more than 87% at 5&#x000a0;mg/ml concentration. This gives indication that the compounds are tolerated and nontoxic for human cells, as the cytotoxic dose was higher than the therapeutic dose on most of microorganisms. It is worth mentioning that the safe limit of the percent of dead cells is not an absolute value and could be more than 10% as reported in previous studies [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Cell viability assay of the potential antimicrobial candidates</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Compound</th><th align="left">Cell viability (%)</th></tr></thead><tbody><tr><td align="left"><bold>9</bold></td><td char="&#x000b1;" align="char">91.51&#x02009;&#x000b1;&#x02009;2.21</td></tr><tr><td align="left"><bold>15</bold></td><td char="&#x000b1;" align="char">88.42&#x02009;&#x000b1;&#x02009;0.91</td></tr><tr><td align="left"><bold>16</bold></td><td char="&#x000b1;" align="char">93.51&#x02009;&#x000b1;&#x02009;1.54</td></tr><tr><td align="left"><bold>18</bold></td><td char="&#x000b1;" align="char">87.18&#x02009;&#x000b1;&#x02009;2.34</td></tr><tr><td align="left"><bold>19</bold></td><td char="&#x000b1;" align="char">92.34&#x02009;&#x000b1;&#x02009;3.37</td></tr><tr><td align="left"><bold>20</bold></td><td char="&#x000b1;" align="char">88.12&#x02009;&#x000b1;&#x02009;1.81</td></tr><tr><td align="left"><bold>29</bold></td><td char="&#x000b1;" align="char">87.58&#x02009;&#x000b1;&#x02009;3.61</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec8"><title>Biofilm inhibition assay</title><p id="Par20">Structured bacterial communities known as biofilms are assemblages of single type or assortment of microorganisms that are linked to one another or to solid surfaces and are submerged in a self-produced, hydrated polymeric matrix that contains polysaccharides, proteins and DNA [<xref ref-type="bibr" rid="CR49">49</xref>]. Compared to free-floating or planktonic cells, biofilm-dwelling bacteria have higher adaptive resistance to antibiotics and host immune defenses, which is largely responsible for their success in causing chronic infections in humans in community-acquired and nosocomial infections especially when they occupy medical implants e.g.: stents, heart valves and catheters. This resistance manifests as a 100&#x02013;1000 fold rise in the minimum inhibitory and/or bactericidal concentrations which can be attributed to a number of factors, including: i) the components of the biofilm as lipids, proteins, polysaccharides and e-DNA act as a physical barrier that prevent antibiotic penetration to biofilm cells [<xref ref-type="bibr" rid="CR50">50</xref>], ii) the fluctuation of oxygen concentrations according to the composition of biofilm, where anaerobic conditions could arise because the oxygen content is lower in the center and relatively high near the top, iii) the metabolic activity of the cells in the biofilm is a function of depth where the more deep areas inside the biofilm are deprived of nutrients and bacteria enter a latent state and become less sensitive to antibiotics because most antibiotics target either DNA replication, cell walls, or protein synthesis, which are either entirely absent from the biofilm-grown bacterial population [<xref ref-type="bibr" rid="CR51">51</xref>] iv) antibiotic-degrading enzymes, low-affinity antibiotic targets and overexpression of efflux pumps for a range of substrates can all be produced concurrently by bacterial cells in biofilms. Due to presence of more conjugation in the biofilm state, mutation and horizontal gene transfer rates are much higher than in the free living state [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Therefore, it is crucial to investigate novel compounds for their capacity to target and eradicate microbial biofilms to boost the antibiotics database, enable more rational use of antibiotics and/or biocides, overcome the high rate of microbial evolution and emergence of resistant strains, and evade the added cost and morbidity ensued by resistant strains infection [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. The example of <italic>P. aeruginosa</italic>&#x02019;s biofilm has been chosen as it has been abovementioned to be fatal especially in the case of nosocomial infection of immunocompromised patients (e.g.: surgical wounds, pneumonia, blood sepsis, etc.) [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. Accordingly, compounds <bold>19</bold> and <bold>20,</bold> which are the most active against <italic>P. aeruginosa</italic>, were selected to evaluate their anti-biofilm activity. Results revealed that compounds <bold>19</bold> and <bold>20</bold> have biofilm inhibition effect with IC<sub>50</sub>&#x02009;=&#x02009;3.55 and 6.86&#x000a0;&#x000b5;M (1.5 and 2.59&#x000a0;&#x000b5;g/ml) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>), respectively. It is noteworthy to point out that the value of the minimal biofilm inhibitory concentration (MBIC) is less than that of the minimum inhibitory concentration (MIC) 0.15&#x000a0;mg/ml for compound <bold>19</bold> and 0.25&#x000a0;mg/ml for compound <bold>20</bold> confirming that the inhibition of the biofilm formation is not ascribed to bacteriostatic or bactericidal effects and hence, have potential of being valuable as anti-virulence agents that do not contribute to antibiotic resistance development. These findings accord with the theories that describe how sub-MIC compromises the bacterial growth and biochemical properties including virulence factors e.g.: biofilm production, cell adhesion, cell surface hydrophobicity (CSH), production of quorum sensing signals, etc. However, it has also been documented that this behavior is strictly strain-dependent. Other studies reported higher MBIC, for the antimicrobial agents under investigation, than their MIC while the sub-MIC induced sessile bacterial aggregation in robust biofilms [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. Hence, it is crucial to determine the effect of sub-MIC doses on bacterial behavior as it can lead to development of superbugs via any of the known mechanisms including, but not limited to, antibiotic degradation, neutralization, expulsion or modification of the target site [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR56">56</xref>].<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Biofilm inhibition assay results depicting the effect of compounds <bold>19</bold> and <bold>20</bold> on the aggregation of Gram (-) <italic>P. aeruginosa</italic> ATCC 27953, in comparison to ciprofloxacin as positive control</p></caption><graphic xlink:href="11030_2024_10830_Fig5_HTML" id="MO7"/></fig></p></sec><sec id="Sec9"><title>Bacterial cell surface hydrophobicity (CSH) assay</title><p id="Par22">As previously described, dense bacterial biofilm aggregates are a primary means for bacterial antibiotic resistance and increased pathogenicity and virulence. Biofilms also serve to protect bacteria, in their natural habitats, against harsh conditions of nutrients depletion or competitors&#x02019; attack by acting as physical barrier. They are an organized network of microbial cells glued together within self-secreted slimy polysaccharide, nucleic acid and protein matrices. CSH stabilizes cellular adhesion in addition to other virulence or metabolic factors that act in favor of intact biofilm clumping and aggregated community protection and propagation. In case of <italic>P. aeruginosa</italic>, these elements include: (i) pyocyanin (N-methyl-1-hydroxyphenazine) secretion that consequently leads to extracellular DNA (eDNA) liberation, an essential component in biofilm establishment, (ii) extracellular proteases that also result in cell lysis and eDNA, (iii) intercellular quorum sensing signals, homoserine lactones or quinolones, that facilitate cell-to-cell communication, (iv) <italic>Pseudomonas</italic> cells undergo a phenotypic decrease in size giving rise to small colony variants (SCV) which are metabolically dormant except for up-regulated biofilm formation genes that allow for increased surface hydrophobicity, (v) hemolysin toxin, as evident by knockout mutants lacking the biofilm formation propensity, and (vi) selective attachment between surface appendages like capsules, pili and S-layer [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR60">60</xref>].</p><p id="Par23">As CSH has been validated as a key factor in biofilm integrity and robustness, <italic>P. aeruginosa</italic> was cultured in presence and absence of different concentrations of the quinazolinone derivatives <bold>19</bold>, <bold>20</bold>. As depicted in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>, it is clear that the two compounds did not behave alike in this regard. While increasing concentrations of compound <bold>20</bold> resulted in reduced hydrophobicity index (ie: decreased CSH as indicated by less <italic>Pseudomonas</italic> cells in the toluene fraction) in a very similar pattern to that of ciprofloxacin, compound <bold>19</bold>, on the other side, had no evident effect on CSH. Despite lacking statistical significance, the slight increase in surface hydrophobicity conferred by subinhibitory concentration of compound <bold>20</bold> might be a demonstration of the cells&#x02019; resilience and/or persistence under stress conditions, and how they adapt for maintenance through the action of RpoS sigma factor. This usually takes place via secreting hydrophobins and membrane vesicles to promote tighter cell attachment, a phenomenon that has been reported before by other biofilm-forming <italic>Pseudomonas</italic>, <italic>Staphylococcus</italic>, <italic>Streptococcus</italic> and <italic>Listeria</italic> strains [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref>]. On the other side, higher concentrations of compound <bold>20</bold>, like the fluoroquinolone ciprofloxacin, increased the charge over the outer cell membrane to induce cell repulsion and reduce cell-to-cell and cell-to-surface accumulation.<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Hydrophobicity index of <italic>Pseudomonas aeruginosa</italic> ATCC 27953 as affected by different concentrations of compounds <bold>19</bold>, <bold>20</bold>. One way ANOVA test (with Tukey&#x02019;s correction for multiple comparisons) shows significant difference between control and each test compound. Mean of 3 independent experiments&#x02009;&#x000b1;&#x02009;SD triplicates, the asterisk indicates the significance of P-value&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="11030_2024_10830_Fig6_HTML" id="MO8"/></fig></p></sec><sec id="Sec10"><title>Inhibition of exopolysaccharide (EPS) production</title><p id="Par24">Exopolysaccharide is one of the viscous matrix components that binds the organized biofilm structure together, making it impervious to host defenses, disinfectants and antimicrobial agents. It is essential in the initial phase of cellular attachment, together with other topographic and secretory predispositions. Since this stage is reversible, preventing or even loosening the cells&#x02019; population assembly can reduce the cost and burden of eradicating the mature and stable biofilm [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Like other virulence determinants, the matrixome production, including EPS, is governed by QS autoinducers among the bacterial community. Relevantly, both mucoid and non-mucoid <italic>P. aeruginosa</italic> secrete at least one of the polysaccharides alginate, Pel and Psl helping the opportunist producers to thrive under versatile environmental conditions as they serve as a structural scaffold and a protective shield [<xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par25">Both compounds <bold>19</bold>, <bold>20</bold> show the same pattern of dose-dependent EPS secretion inhibition, similar to ciprofloxacin&#x02019;s, regardless of the different intensities (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). A reduction in EPS production up to&#x02009;~&#x02009;60% was recorded for both of the investigated compounds, for double the MIC dose, surpassing that of ciprofloxacin which was&#x02009;~&#x02009;16%. Furthermore, it is pivotal to highlight the fact that compound <bold>19</bold> marked&#x02009;&#x0003e;&#x02009;50% EPS reduction at only 1/4 of the MIC ie: it interferes with the biofilm community without being lethal to the bacteria. Hence, it can be considered as a potential anti-virulence agent to be used in combination with other antibiotics to decrease the possible tendency for induced resistance.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Reduction of exopolysaccharide (EPS) production from <italic>Pseudomonas aeruginosa</italic> ATCC 27953 via different test compounds concentrations</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Compound</th><th align="left">Concentration</th><th align="left">% EPS inhibition</th></tr></thead><tbody><tr><td align="left" rowspan="3">Ciprofloxacin</td><td align="left">1/4 MIC</td><td char="&#x000b1;" align="char">1.46&#x02009;&#x000b1;&#x02009;0.28</td></tr><tr><td align="left">1 MIC</td><td char="&#x000b1;" align="char">8.98&#x02009;&#x000b1;&#x02009;0.52</td></tr><tr><td align="left">2 MIC</td><td char="&#x000b1;" align="char">16.54&#x02009;&#x000b1;&#x02009;0.61</td></tr><tr><td align="left" rowspan="3"><bold>19</bold></td><td align="left">1/4 MIC</td><td char="&#x000b1;" align="char">54.15&#x02009;&#x000b1;&#x02009;4.00</td></tr><tr><td align="left">1 MIC</td><td char="&#x000b1;" align="char">55.93&#x02009;&#x000b1;&#x02009;3.31</td></tr><tr><td align="left">2 MIC</td><td char="&#x000b1;" align="char">63.79&#x02009;&#x000b1;&#x02009;2.70</td></tr><tr><td align="left" rowspan="3"><bold>20</bold></td><td align="left">1/4 MIC</td><td char="&#x000b1;" align="char">21.51&#x02009;&#x000b1;&#x02009;3.26</td></tr><tr><td align="left">1 MIC</td><td char="&#x000b1;" align="char">47.84&#x02009;&#x000b1;&#x02009;3.00</td></tr><tr><td align="left">2 MIC</td><td char="&#x000b1;" align="char">61.50&#x02009;&#x000b1;&#x02009;2.83</td></tr></tbody></table><table-wrap-foot><p>The data shown are the means&#x02009;&#x000b1;&#x02009;standard errors</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Twitching motility assay</title><p id="Par27">
Bacterial motility is an additional fundamental feature facilitating accumulation and adherence tosurfaces. Four different types of motilities were described for <italic>P. aeruginosa</italic> namely; sliding, swimming, swarming and twitching, which are governed through quorum sensing systems while the blocking thereof compromised the biofilms&#x02019; integrity and architecture [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. Twitching motility, in particular, is deemed responsible for the initial stages of free flowing cells settling and colonization of different substrata, and is mediated by polar monotrichous flagella and/or type-IV pili [<xref ref-type="bibr" rid="CR57">57</xref>]. Both compounds <bold>19</bold>, <bold>20</bold> reduced the magnitude <italic>P. aeruginosa</italic> twitching motility (Fig. <xref rid="Fig7" ref-type="fig">7</xref>). Compound <bold>20</bold> remarkably blocked this type of motility starting from sub-MIC equal to half the MIC dose, similar to previous data from cephalosporins, clarithromycin and piperacillin/tazobactam [<xref ref-type="bibr" rid="CR65">65</xref>]. Compound <bold>19</bold> could only abolish 30% of the twitching at the highest tested concentration (= MIC). Thus, motility inhibition, together with the other aforementioned virulence factors, can be a valid assessment for rhl and las QS quenching in the early stages of biofilm formation [<xref ref-type="bibr" rid="CR58">58</xref>], whereas the significance of pqs is mainly evident in the late steps of dense biofilm maturity and maintenance due to the limited inducer permeability within the matrixome and short range of bioreporting. Its impact is witnessed through managing autolysis, rhamnolipid EPS secretion, and Fe<sup>3+</sup> scavenging blocking pyoverdine and pyochelin synthesis pathways. As indicated before, bacterial growth is not necessarily influenced in the process since quorum quenching takes place entirely extracellularly [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Intriguingly, the investigated quinazolinone derivatives share structural resemblance with the quinolone inducers of the pqs system. Thus, it could be easily assumed that the synthetic mimicking analogues perturb the QS by (i) downregulating the pqs signals biosynthesis or activation or both, or (ii) antagonizing the endogenous canonical autoinducer-receptor binding [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Twitching motility reduction of <italic>Pseudomonas aeruginosa</italic> ATCC 27953 via different concentrations of compounds <bold>19</bold>, <bold>20</bold>. (I) Comparison of twitching motility zones in comparison to the negative control (DMF). One way ANOVA test (with Tukey&#x02019;s correction for multiple comparisons) shows significant difference between control and test compounds. Mean of 3 independent experiments&#x02009;&#x000b1;&#x02009;SD triplicates, the asterisk indicates the significance of P-value&#x02009;&#x0003c;&#x02009;0.0001. (II) Illustration of motility under the influence of the addition of compounds <bold>19, 20</bold> at (a) 1/4 concentration of MIC, (b) 1/2 concentration of MIC, and (c) MIC</p></caption><graphic xlink:href="11030_2024_10830_Fig7_HTML" id="MO9"/></fig></p></sec><sec id="Sec12"><title>Molecular docking study</title><p id="Par28">Biofilm formation in bacteria is a quorum sensing-controlled mechanism. Consequently, molecular docking study was performed to explain the anti-biofilm activity of compounds <bold>19</bold> and <bold>20</bold>. The binding mode of the co-crystallized inhibitor (M64) in the PqsR ligand binding domain (LBD) was initially examined. The protocol used for docking was validated by re-docking of the co-crystallized ligand (M64) in the ligand binding site with RMSD of 0.5036&#x000a0;&#x000c5; (C-Docker interaction energy&#x02009;=&#x02009;-52.21&#x000a0;kcal/mol) (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>A). Also, the carbonyl group of the amide functionality of docking pose was able to reproduce the essential hydrogen bond performed by the co-crystallized ligand with the key amino acids Gln194 and Pro238 (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>B). The validation step outputs indicated the appropriateness of the used protocol for the molecular docking study of the test compounds in the LBD of PqsR.<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p><bold>A</bold> Superimposition of the co-crystalized (cyan) and the docking pose (pink) of M64 in the LBD PqsR of <italic>P. aeruginosa</italic> with RMSD of 0.5036&#x000a0;&#x000c5;. <bold>B</bold> Binding of the co-crystalized inhibitor M64 in the LBD of PqsR of <italic>P. aeruginosa</italic></p></caption><graphic xlink:href="11030_2024_10830_Fig8_HTML" id="MO10"/></fig></p><p id="Par29">The docking results showed that compounds <bold>19</bold> and <bold>20</bold> had C-Docker interaction energy&#x02009;=&#x02014;49.62&#x000a0;kcal/mol and &#x02013; 47.61&#x000a0;kcal/mol, respectively that are near to M64. In compound <bold>19</bold> the N-1 of the quinazolinone ring acts as a hydrogen bond acceptor where it forms a hydrogen bond with key amino acid Gln194. In addition the carbonyl group makes a hydrogen bond with Leu208. Moreover, it is further stabilized through hydrophobic interactions with the hydrophobic side chains of the amino acids Ala102, lle149, Ala168, Phe221, Leu207 and Leu208 and lle236 (Fig.&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>). These hydrophobic residues are also important in the formation of the hydrophobic pocket which mediates PqsR interaction with other quinazolinone inhibitors [<xref ref-type="bibr" rid="CR31">31</xref>]. Compound <bold>20</bold> successfully forms four hydrogen bonds with the LBD of PqsR. The nitrogen at position 1 of quinazolinone makes the essential hydrogen bond with Gln194 side chain, while he nitrogen of the pyrrolidine ring forms a hydrogen bond with amino acid Leu197 backbone. In addition, the <italic>p</italic>-nitro phenyl ring exhibits two hydrogen bonds with Pro238 and Thr265 side chains. Worth mentioning that performing a hydrogen bond with Thr265 residue was also reported for other PqsR inhibitors [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR66">66</xref>]. The <italic>p</italic>-nitro phenyl moiety is directed towards a hydrophobic pocket bordered by Ala102, lle149, Ala168 and lle236 residues. Also, the complex is further stabilized through hydrophobic interactions between the prrolidinyl moiety and the side chain of Ala130, His204 and Pro210 amino acids (Fig.&#x000a0;<xref rid="Fig10" ref-type="fig">10</xref>). The results of good interactions of compounds <bold>19</bold> and <bold>20</bold> with the LBD of PqsR indicate that these compounds reduce biofilm formation through their antagonistic activity on of PqsR.<fig id="Fig9"><label>Fig.&#x000a0;9</label><caption><p>2D diagram (<bold>A</bold>) and 3D representation (<bold>B</bold>) illustrating the interactions of compound <bold>19</bold> within the active site of the LBD of PqsR of <italic>P. aeruginosa</italic></p></caption><graphic xlink:href="11030_2024_10830_Fig9_HTML" id="MO11"/></fig><fig id="Fig10"><label>Fig.&#x000a0;10</label><caption><p>2D diagram (<bold>A</bold>) and 3D representation (<bold>B</bold>) illustrating the interactions of compound <bold>20</bold> within the active site of the LBD of PqsR of <italic>P. aeruginosa</italic></p></caption><graphic xlink:href="11030_2024_10830_Fig10_HTML" id="MO12"/></fig></p></sec></sec><sec id="Sec13"><title>Conclusion</title><p id="Par30">Bacterial resistance to antimicrobial agents has been potentiated over the last years due to their overuse, wrong prescribing, misuse in agriculture and livestock breeding, and refraining of pharmaceutical companies from investing in new antibiotic entities on account of financial and regulatory reasons. On this basis, this study aimed to design and synthesize novel quinazolin-4-ones because of the history of this class members as efficient antimicrobial hits. Compounds with broad spectrum were validated for their safety against human cell line, which promotes their appropriateness for clinical use. Further driven by the struggle against microbial resistance phenomenon, the most promising candidates <bold>19</bold> and <bold>20</bold> were selected for biofilm fighting evaluation which indicates the quorum sensing interruption. Both compounds were able to inhibit biofilm formation at concentrations below their MIC and hence, decreasing the probability of resistance development. The activities against other virulence factors (twitching motility, cell surface hydrophobicity reduction, exopolysaccharide production) were also correlated in an attempt to envisage the biofilm digestion mechanism. This was furthermore corroborated by molecular docking studies that illustrated the binding mode of the investigated compounds on the binding site of <italic>Pseudomonas aeruginosa</italic> quorum sensing transcriptional regulator PqsR<italic>.</italic> Finally, we anticipate to highlight that there is still room for developing new antibiotic molecules that can act without triggering resistance reaction. It is also critical to raise the scientific community and public awareness, and urge research efforts and regulatory decrees to be dedicated to coordinate efforts against this worldwide crisis.</p></sec><sec id="Sec14"><title>Experimental</title><sec id="Sec15"><title>Chemical synthesis</title><sec id="Sec16"><title>General</title><p id="Par31">Melting points were determined by the Electrothermal Capillary apparatus and were uncorrected. Purity of the final compounds detected by HPLC. HPLC analysis was carried out using Agilent 1100 series apparatus equipped with a quaternary pump, a vacuum de-gasser and detection method was using diode array (DAD) ultraviolet (UV) detector at 254&#x000a0;nm and HP Chemstation software. Column used was C18 column Zorbax ODS (4.6&#x02009;&#x000d7;&#x02009;150&#x000a0;mm i.d., 5&#x000a0;mm). IR spectra were recorded as KBr pellets with [JASCO FT/IR-6100 spectrometer] and the values were characterized in cm<sup>&#x02212;1</sup>. <sup>1</sup>H- and <sup>13</sup>C NMR spectra were recorded at 400 (100) MHz Bruker Spectrometer and chemical shift values were recorded in ppm. Mass spectral data were measured with Thermo Scientific ISQ single quadrupole mass spectrometer at 70&#x000a0;eV ionization energy. Column chromatography was performed by using silica gel as a stationary phase.</p><sec id="Sec17"><title>Synthesis of methyl 2-(2-chloroacetamido)benzoate (3)</title><p id="Par32">A mixture of 3.64&#x000a0;mmol of methyl anthranilate (<bold>2</bold>) and 7.28&#x000a0;mmol of triethylamine in dichloromethane was stirred at 0&#x000a0;&#x000b0;C for 15&#x000a0;min. Chloroacetyl chloride (4.37&#x000a0;mmol) in dichloromethane was added dropwise while maintaining the temperature at 0&#x000a0;&#x000b0;C. The reaction was stirred at 25&#x000a0;&#x000b0;C for 3&#x000a0;h, quenched with water, the organic layer was dried over anhydrous sodium sulphate and evaporated to get compound <bold>3</bold> as buff solid in 70% yield m.p. 98&#x000a0;&#x000b0;C (Lit. [<xref ref-type="bibr" rid="CR67">67</xref>] m.p. 95&#x02013;96&#x000a0;&#x000b0;C).</p></sec><sec id="Sec18"><title>General procedure for synthesis of methyl 2-[2-(amino)acetamido]benzoates 4a-d</title><p id="Par33">A mixture of 0.1&#x000a0;mmol of compound <bold>3</bold> and 0.1&#x000a0;mmol of NaI in acetone was refluxed for one hour followed by addition of 0.2&#x000a0;mmol of the appropriate secondary amine. The mixture was further refluxed for 3&#x000a0;h. After cooling to room temperature, the mixture was filtered and the filtrate was evaporated under reduced pressure. The residue was washed with water and extracted with ethyl acetate. The organic layer was dried and evaporated to get <bold>4</bold> in pure form.<list list-type="bullet"><list-item><p id="Par34">Methyl 2-[2-(diethylamino)acetamido]benzoate (<bold>4a</bold>) Yellow oil, yield 88% [<xref ref-type="bibr" rid="CR37">37</xref>].</p></list-item><list-item><p id="Par35">Methyl 2-[2-(pyrrolidin-1-yl)acetamido]benzoate (<bold>4b</bold>) Could not be prepared in good yield.</p></list-item><list-item><p id="Par36">Methyl 2-[2-(piperidin-1-yl)acetamido]benzoate (<bold>4c</bold>) White solid, 85% yield, m.p. 94&#x000a0;&#x000b0;C (Lit. [<xref ref-type="bibr" rid="CR37">37</xref>] m.p. 96&#x02013;97&#x000a0;&#x000b0;C).</p></list-item><list-item><p id="Par37">Methyl 2-(2-morpholinoacetamido)benzoate (<bold>4d</bold>) White solid, 80% yield, m.p. 92&#x000a0;&#x000b0;C (Lit. [<xref ref-type="bibr" rid="CR37">37</xref>] m.p. 90.5&#x02013;93&#x000a0;&#x000b0;C).</p></list-item></list></p></sec><sec id="Sec19"><title>Synthesis of 2-(2-chloroacetamido)benzoic acid (6)</title><p id="Par38">A mixture of 3.64&#x000a0;mmol of anthranilic acid (<bold>1</bold>) and 7.28&#x000a0;mmol of triethylamine in dichloromethane was stirred at 0&#x000a0;&#x000b0;C for 15&#x000a0;min. Chloroacetyl chloride (4.37&#x000a0;mmol) in dichloromethane was added dropwise while maintaining the temperature at 0&#x000a0;&#x000b0;C. The reaction was stirred at 25&#x000a0;&#x000b0;C for 3&#x000a0;h. The formed suspension was filtrated and the residue was washed several times with distilled water followed by crystallization from ethanol to obtain compound <bold>6</bold> as white crystals in 75% yield m.p. 184&#x000a0;&#x000b0;C (Lit. [<xref ref-type="bibr" rid="CR67">67</xref>] m.p. 180&#x02013;182&#x000a0;&#x000b0;C). <sup>1</sup>H NMR (400&#x000a0;MHz DMSO) &#x003b4; 11.81 (s, 1H), 8.52 (d, <italic>J</italic>&#x02009;=&#x02009;8.36&#x000a0;Hz, 1H), 8.02 (d, <italic>J</italic>&#x02009;=&#x02009;7.84&#x000a0;Hz, 1H), 7.63 (t, <italic>J</italic>&#x02009;=&#x02009;15.6, 7.68&#x000a0;Hz, 1H), 7.22 (t, <italic>J</italic>&#x02009;=&#x02009;15.16, 7.56&#x000a0;Hz, 1H), 4.44 (s, 2H). <sup>13</sup>C NMR (100&#x000a0;MHz, DMSO) &#x003b4; 169.76, 165.71, 140.32, 134.62, 131.65, 123.95, 120.30, 117.33, 43.89.</p></sec><sec id="Sec20"><title>Synthesis of 2-(chloromethyl)-4H-benzo[d][1,3]oxazin-4-one (7)</title><p id="Par39">A solution of 10&#x000a0;mmol of <bold>6</bold> in 8&#x000a0;ml acetic anhydride was refluxed for one hour. The mixture was evaporated under vacuum till dryness. The obtained residue was purified by column chromatography using DCM as mobile phase to achieve the benzoxzaine <bold>7</bold> as buff solid in 70% yield m.p. 92&#x000a0;&#x000b0;C (Lit. [<xref ref-type="bibr" rid="CR44">44</xref>] m.p. 93&#x02013;94&#x000a0;&#x000b0;C). <sup>1</sup>H NMR (400&#x000a0;MHz DMSO) &#x003b4; 8.12&#x02013;8.14 (m, 1H), 7.94&#x02013;7.98 (m, 1H), 7.65&#x02013;7.69 (m, 2H), 4.69 (s, 2H). <sup>13</sup>C NMR (100&#x000a0;MHz, DMSO) &#x003b4; 158.92, 157.52, 145.73, 137.55, 129.92, 128.60, 127.28, 117.24, 42.47.</p></sec><sec id="Sec21"><title>Synthesis of 3-amino-2-(chloromethyl)quinazolin-4(3<italic>H</italic>)-one (8)</title><p id="Par40">To an ethanolic solution of 0.1&#x000a0;mmol benzoxazine <bold>7</bold> one equivalent hydrazine hydrate (98%) was added and the mixture was refluxed for 2&#x000a0;h. The solvent was evaporated and the residue was purified by column chromatography using a mixture of DCM:EtOAc 9:1 to obtain compound <bold>8</bold> as white solid in 30% yield m.p. 152&#x000a0;&#x000b0;C (Lit. [<xref ref-type="bibr" rid="CR68">68</xref>] m.p. 156&#x000a0;&#x000b0;C). IR (KBr, cm<sup>&#x02212;1</sup>): 3301, 3204 (NH<sub>2</sub>), 2983 (C=C), 1670 (C=O), 1599 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz DMSO) &#x003b4; 8.15&#x02013;8.17 (m, 1H), 7.84&#x02013;7.87 (m, 1H), 7.70 (d,<italic> J</italic>&#x02009;=&#x02009;8.00&#x000a0;Hz, 1H), 7.56&#x02013;7.60 (m, 1H), 5.75 (s, 2H), 4.89 (s, 2H).<sup>13</sup>C NMR (100&#x000a0;MHz, DMSO) &#x003b4; 161.15, 154.10, 146.62, 134.90, 127.76, 127.70, 126.02, 122.02, 43.49. MS (EI) m/z (%): 209.03 (M<sup>+</sup>, 54.5).</p></sec><sec id="Sec22"><title>General procedure for synthesis of quinazolin-4(3<italic>H</italic>)-ones 5a-d</title><p id="Par41"><bold>Method A</bold>: A mixture of 0.05&#x000a0;mol of <bold>4</bold> derivatives and 30&#x000a0;ml of hydrazine hydrate (98%) in 120&#x000a0;ml n-butanol was refluxed overnight. After cooling to room temperature the solvent was evaporated and the obtained solid was crystallized from ethanol to get the cyclized 4-quinazolinones <bold>5</bold> in pure form.</p><p id="Par42"><bold>Method B</bold>: Two equivalents of the appropriate secondary amine was added to a solution of 0.1&#x000a0;mmol of compound <bold>8</bold> in benzene. The mixture was refluxed overnight, cooled, quenched with distilled water, the organic layer was dried and evaporated to get <bold>5</bold> in pure form.</p></sec><sec id="Sec23"><title>3-Amino-2-[(diethylamino)methyl]quinazolin-4(3<italic>H</italic>)-one (5a) [<xref ref-type="bibr" rid="CR37">37</xref>] Prepared by methods A and B</title><p id="Par43">Yellow oil. <sup>1</sup>H NMR (400&#x000a0;MHz CDCl<sub>3</sub>) &#x003b4; 8.19 (d, <italic>J</italic>&#x02009;=&#x02009;7.6&#x000a0;Hz 1H), 7.61&#x02013;7.68 (m, 2H), 7.39&#x02013;7.43 (m, 1H), 6.51 (br s, 2H), 3.83 (s, 2H), 2.58 (q, <italic>J</italic>&#x02009;=&#x02009;14.4&#x000a0;Hz, 4H), 0.98 (t, <italic>J</italic>&#x02009;=&#x02009;14.4&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 158.83, 151.14, 146.23, 133.65, 127.36, 126.60, 126.32, 119.94, 57.71, 47.09, 11.41. MS (EI) m/z (%): 247.11 (M<sup>+</sup>, 9.2).</p></sec><sec id="Sec24"><title>3-Amino-2-(pyrrolidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (5b) Prepared by method B only</title><p id="Par44">White solid, m.p. 100&#x000a0;&#x000b0;C. <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.26&#x02013;8.28 (m, 1H), 7.69 &#x02013; 7.75 (m, 2H), 7.45 &#x02013; 7.49 (m, 1H), 6.41 (br s, 2H), 3.95 (s, 2H), 2.65 (s, 4H), 1.79 (dd, <italic>J</italic>&#x02009;=&#x02009;10.2, 3.2&#x000a0;Hz, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 158.58, 151.28, 146.16, 133.65, 127.41, 126.61, 126.29, 119.97, 58.77, 53.64, 23.46. MS (EI) m/z (%): 245.09 (M<sup>+</sup>&#x02009;+&#x02009;1, 100).</p></sec><sec id="Sec25"><title>3-Amino-2-(piperidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (5c) Prepared by methods A and B</title><p id="Par45">White solid, m.p. 98&#x000a0;&#x000b0;C (Lit. [<xref ref-type="bibr" rid="CR37">37</xref>] m.p. 101&#x02013;103&#x000a0;&#x000b0;C). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.26 &#x02013; 8.28 (m, 1H), 7.68 &#x02013; 7.74 (m, 2H), 7.45 (ddd, <italic>J</italic>&#x02009;=&#x02009;8.2, 6.2, 2.1&#x000a0;Hz, 1H), 6.54 (br s, 2H), 3.76 (s, 2H), 2.54 (br s, 4H), 1.53&#x02013;1.58 (m, 4H), 1.45 (d, <italic>J</italic>&#x02009;=&#x02009;5.0&#x000a0;Hz, 2H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 158.76, 150.46, 146.16, 133.68, 127.27, 126.57, 126.17, 119.97, 62.40, 54.34, 25.65, 23.87.</p></sec><sec id="Sec26"><title>3-Amino-2-(morpholinomethyl)quinazolin-4(3<italic>H</italic>)-one (5d) Prepared by methods A and B</title><p id="Par46">White solid, m.p. 120&#x02013;122&#x000a0;&#x000b0;C (Lit. [<xref ref-type="bibr" rid="CR37">37</xref>] m.p. 126&#x02013;127&#x000a0;&#x000b0;C). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.24 (d, <italic>J</italic>&#x02009;=&#x02009;7.88&#x000a0;Hz, 1H), 7.69&#x02013;7.74 (m, 2H), 7.47 (d, <italic>J</italic>&#x02009;=&#x02009;8&#x000a0;Hz, 1H), 6.21 (br s, 2H), 3.84 (s, 2H), 3.71 (s, 4H), 2.66 (s, 4H). <sup>13</sup>C NMR (100&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 158.34, 149.15, 145.09, 132.89, 126.46, 125.94, 125.37, 119.07, 65.71, 60.69, 52.36.</p></sec><sec id="Sec27"><title>General procedure for synthesis of 3-(benzylideneamino)-2-yl-quinazolin-4(3<italic>H</italic>)-ones 9&#x02013;32</title><p id="Par47">An ethanolic equimolar solution of the primary amine derivative <bold>5a</bold>-<bold>d</bold> and the appropriate aldehyde in presence of few drops of glacial acetic acid was refluxed overnight. Ethanol was evaporated, the residue was washed with distilled water and extracted with EtOAc. The organic layer was dried and evaporated to get the final Schiff bases <bold>9</bold>&#x02013;<bold>32</bold> in crude form which were purified by gradient elution column chromatography using a mixture of DCM:EtOAc:Methanol as mobile phase.</p></sec><sec id="Sec28"><title>3-(Benzylideneamino)-2-[(diethylamino)methyl]quinazolin-4(3<italic>H</italic>)-one (9)</title><p id="Par48">White solid, m.p. 78&#x000a0;&#x000b0;C, yield 75%, HPLC: purity 98.34%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;3.42&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1676 (C=O), 1601 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.82 (s, 1H), 8.32 (d, <italic>J</italic>&#x02009;=&#x02009;8.3&#x000a0;Hz, 1H), 7.92 (d, <italic>J</italic>&#x02009;=&#x02009;1.6&#x000a0;Hz, 2H), 7.82 &#x02013; 7.72 (m, 2H), 7.61 &#x02013; 7.46 (m, 4H), 3.86 (s, 2H), 2.68 (q, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 4H), 0.97 (t, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 6H).<sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 168.97, 158.63, 153.47, 146.36, 134.04, 132.68, 132.46, 128.97, 128.87, 127.63, 127.12, 126.66, 121.75, 56.32, 46.95, 11.51. MS (EI) m/z (%): 335.24 (M<sup>+</sup>&#x02009;+&#x02009;1, 41.12). Anal. calcd. for C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>O: C, 71.83; H, 6.63; N, 16.75. Found: C, 71.97; H, 6.82; N, 16.88.</p></sec><sec id="Sec29"><title>3-[(4-Chlorobenzylidene)amino]-2-[(diethylamino)methyl]quinazolin-4(3<italic>H</italic>)-one (10)</title><p id="Par49">White solid, m.p. 124&#x000a0;&#x000b0;C, yield 81%, HPLC: purity 98.69%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;6.74&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1681 (C=O), 1597 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.84 (s, 1H), 8.32 (d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x000a0;Hz, 1H), 7.87 (d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x000a0;Hz, 2H), 7.81 &#x02013; 7.74 (m, 2H), 7.55 &#x02013; 7.47 (m, 3H), 3.87 (s, 2H), 2.69 (d, <italic>J</italic>&#x02009;=&#x02009;6.5&#x000a0;Hz, 4H), 0.97 (t, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 6H).<sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 167.27, 158.62, 146.26, 138.62, 134.17, 131.21, 130.07, 129.29, 127.66, 127.16, 126.79, 121.69, 56.46, 46.98, 11.50. MS (EI) m/z (%): 369.23 (M<sup>+</sup>&#x02009;+&#x02009;1, 38.81). Anal. calcd. for C<sub>20</sub>H<sub>21</sub>ClN<sub>4</sub>O: C, 65.12; H, 5.74; N, 15.19. Found: C, 65.37; H, 5.96; N, 15.27.</p></sec><sec id="Sec30"><title>2-[(Diethylamino)methyl]-3-[(4-methylbenzylidene)amino]quinazolin-4(3<italic>H</italic>)-one (11)</title><p id="Par50">White solid, m.p. 74&#x000a0;&#x000b0;C, yield 70%, HPLC: purity 98.81%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;4.72&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1681 (C=O), 1599 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.74 (s, 1H), 8.32 (dd, <italic>J</italic>&#x02009;=&#x02009;8.0, 0.7&#x000a0;Hz, 1H), 7.82 (d, <italic>J</italic>&#x02009;=&#x02009;8.1&#x000a0;Hz, 2H), 7.75 (dd, <italic>J</italic>&#x02009;=&#x02009;16.8, 1.9&#x000a0;Hz, 2H), 7.49 (ddd, <italic>J</italic>&#x02009;=&#x02009;8.2, 6.6, 1.8&#x000a0;Hz, 1H), 7.32 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x000a0;Hz, 2H), 3.85 (s, 2H), 2.68 (q, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 4H), 2.45 (s, 3H), 0.97 (t, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 169.18, 158.66, 153.50, 146.39, 143.18, 133.96, 129.97, 129.62, 129.00, 127.61, 127.09, 126.59, 121.77, 56.28, 46.93, 21.76, 11.51. MS (EI) m/z (%): 348.39 (M<sup>+</sup>, 43). Anal. calcd. for C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O: C, 72.39; H, 6.94; N, 16.08. Found: C, 72.55; H, 7.11; N, 16.24.</p></sec><sec id="Sec31"><title>2-[(Diethylamino)methyl]-3-[(4-methoxybenzylidene)amino]quinazolin-4(3<italic>H</italic>)-one (12)</title><p id="Par51">White solid, m.p. 102&#x02013;104&#x000a0;&#x000b0;C, yield 83%, HPLC: purity 98.67%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;5.06&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1675 (C=O), 1598 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.66 (s, 1H), 8.32 (d, <italic>J</italic>&#x02009;=&#x02009;8.6&#x000a0;Hz, 1H), 7.87 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 7.80 &#x02013; 7.72 (m, 2H), 7.52 &#x02013; 7.45 (m, 1H), 7.02 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 3.90 (s, 3H), 3.84 (s, 2H), 2.68 (d, <italic>J</italic>&#x02009;=&#x02009;7.0&#x000a0;Hz, 4H), 0.97 (t, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 168.87, 163.14, 158.73, 153.21, 146.40, 133.92, 130.87, 127.59, 127.06, 126.56, 125.26, 121.76, 114.34, 56.23, 55.46, 46.95, 11.50. MS (EI) m/z (%): 365.26 (M<sup>+</sup>&#x02009;+&#x02009;1, 61.48). Anal. calcd. for C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>: C, 69.21; H, 6.64; N, 15.37. Found: C, 69.42; H, 6.87; N, 15.45.</p></sec><sec id="Sec32"><title>2-[(Diethylamino)methyl]-3-[(3,4,5-trimethoxybenzylidene)amino]quinazolin-4(3<italic>H</italic>)-one (13)</title><p id="Par52">White solid, m.p. 116&#x000a0;&#x000b0;C, yield 70%, HPLC: purity 98.78%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;6.08&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1672 (C=O), 1601 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.69 (s, 1H), 8.31 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x000a0;Hz, 1H), 7.80 &#x02013; 7.71 (m, 2H), 7.52 &#x02013; 7.45 (m, 1H), 7.17 (s, 2H), 3.96 (s, 3H), 3.93 (s, 6H), 3.86 (s, 2H), 2.70 (d, <italic>J</italic>&#x02009;=&#x02009;6.9&#x000a0;Hz, 4H), 0.99 (t, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 168.73, 158.66, 153.50, 146.31, 141.92, 134.06, 127.78, 127.62, 127.11, 126.70, 121.68, 106.14, 61.03, 56.25, 47.00, 11.57. MS (EI) <italic>m/z</italic> (%): 425.2 (M<sup>+</sup> &#x02009;+&#x02009;1, 2.74). Anal. calcd. for C<sub>23</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>: C, 65.08; H, 6.65; N, 13.20. Found: C, 65.31; H, 6.73; N, 13.38.</p></sec><sec id="Sec33"><title>2-[(Diethylamino)methyl]-3-[(4-nitrobenzylidene)amino]quinazolin-4(3<italic>H</italic>)-one (14)</title><p id="Par53">Yellow solid, m.p. 155&#x000a0;&#x000b0;C, yield 75%, HPLC: purity 99.25%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;6.73&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1676 (C=O), 1603 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 9.15 (s, 1H), 8.37 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 8.32 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x000a0;Hz, 1H), 8.10 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 7.80 (d, <italic>J</italic>&#x02009;=&#x02009;4.3&#x000a0;Hz, 2H), 7.59 &#x02013; 7.47 (m, 1H), 3.92 (s, 2H), 2.71 (d, <italic>J</italic>&#x02009;=&#x02009;6.7&#x000a0;Hz, 4H), 0.98 (t, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 6H).<sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 164.51, 158.68, 149.93, 146.06, 138.63, 134.49, 129.48, 127.77, 127.27, 127.06, 124.09, 121.60, 47.02, 11.51. MS (EI) <italic>m/z</italic> (%): 380.2 (M<sup>+</sup> &#x02009;+&#x02009;1, 1.4). Anal. calcd. for C<sub>20</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>: C, 63.31; H, 5.58; N, 18.46. Found: C, 63.49; H, 5.82; N, 18.83.</p></sec><sec id="Sec34"><title>3-(Benzylideneamino)-2-(pyrrolidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (15)</title><p id="Par54">White solid, m.p. 108&#x02013;110&#x000a0;&#x000b0;C, yield 72%, HPLC: purity 97.74%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;5.28&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1677 (C=O), 1589 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.98 (s, 1H), 8.32 (m, 1H), 7.92 (m, 2H), 7.81 (m, 1H), 7.76 (m, 1H), 7.52 (m, 4H), 3.97 (s, 2H), 2.77 (m, 4H), 1.82 (m, 4H).<sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 167.76, 158.81, 152.98, 146.49, 134.21, 132.89, 132.61, 129.07, 129.00, 127.93, 127.19, 126.79, 121.80, 57.85, 54,47, 23.79. MS (EI) <italic>m/z</italic> (%): 332.52 (M<sup>+</sup>, 44.6). Anal. calcd. for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O: C, 72.27; H, 6.06; N, 16.86. Found: C, 72.47; H, 6.22; N, 17.11.</p></sec><sec id="Sec35"><title>3-[(4-Chlorobenzylidene)amino]-2-(pyrrolidin-1-ylmethyl).quinazolin-4(3<italic>H</italic>)-one (16)</title><p id="Par55">White solid, m.p. 138&#x000a0;&#x000b0;C, yield 79%, HPLC: purity 98.11%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;6.68&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1677 (C=O), 1589 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.99 (s, 1H), 8.30 (dd, <italic>J</italic>&#x02009;=&#x02009;8.0, 1.0&#x000a0;Hz, 1H), 7.84 (d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x000a0;Hz, 2H), 7.82 &#x02013; 7.72 (m, 2H), 7.52 &#x02013; 7.44 (m, 3H), 3.94 (s, 2H), 2.74 (br s, 4H), 1.80 (dt, <italic>J</italic>&#x02009;=&#x02009;6.5, 3.1&#x000a0;Hz, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 165.86, 158.71, 152.88, 146.30, 138.58, 134.16, 131.34, 129.95, 129.33, 127.82, 127.06, 126.73, 121.62, 57.83, 54.34, 23.67. MS (EI) <italic>m/z</italic> (%): 366.7 (M<sup>+</sup>, 1.82). Anal. calcd. for C<sub>20</sub>H<sub>19</sub>ClN<sub>4</sub>O: C, 65.48; H, 5.22; N, 15.27. Found: C, 65.87; H, 5.52; N, 15.41.</p></sec><sec id="Sec36"><title>3-[(4-Methylbenzylidene)amino]-2-(pyrrolidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (17)</title><p id="Par56">White solid, m.p. 156&#x000a0;&#x000b0;C, yield 69%, HPLC: purity 98.07%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;8.21&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1681 (C=O), 1606 (C=N). <sup>1</sup>H NMR (500&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.84 (s, 1H), 8.29 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x000a0;Hz, 1H), 7.78 (d, <italic>J</italic>&#x02009;=&#x02009;8.1&#x000a0;Hz, 3H), 7.77 &#x02013; 7.70 (m, 1H), 7.46 (t, <italic>J</italic>&#x02009;=&#x02009;8.0&#x000a0;Hz, 1H), 7.30 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x000a0;Hz, 2H), 3.91 (s, 2H), 2.72 (s, 3H), 2.43 (s, 4H), 1.78 (s, 4H). <sup>13</sup>C NMR (126&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 168.28, 158.43, 153.19, 146.64, 142.80, 133.74, 130.15, 129.95, 129.13, 127.93, 127.11, 126.71, 121.40, 57.86, 54.58, 23.60, 21.67. MS (EI) <italic>m/z</italic> (%): 347.22 (M<sup>+</sup> &#x02009;+&#x02009;1, 12.92). Anal. calcd. for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O: C, 72.81; H, 6.40; N, 16.17. Found: C, 73.14; H, 6.72; N, 16.32.</p></sec><sec id="Sec37"><title>3-[(4-Methoxybenzylidene)amino]-2-(pyrrolidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (18)</title><p id="Par57">White solid, m.p. 118&#x02013;120&#x000a0;&#x000b0;C, yield 75%, HPLC: purity 96.91%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;7.14&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1678 (C=O), 1601 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.81 (s, 1H), 8.32 (dd, <italic>J</italic>&#x02009;=&#x02009;8.0, 1.0&#x000a0;Hz, 1H), 7.88 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 7.77 (ddd, <italic>J</italic>&#x02009;=&#x02009;12.8, 9.7, 4.8&#x000a0;Hz, 2H), 7.53 &#x02013; 7.46 (m, 1H), 7.03 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 3.96 (s, 2H), 3.92 (s, 3H), 2.80 (s, 4H), 1.83 (s, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 167.66, 163.20, 158.73, 152.74, 146.42, 133.96, 130.78, 127.77, 127.01, 126.58, 125.31, 121.71, 114.42, 57.55, 55.49, 54.31, 23.70. MS (EI) <italic>m/z</italic> (%): 363.28 (M<sup>+</sup> &#x02009;+&#x02009;1, 19.49). Anal. calcd. for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>: C, 69.59; H, 6.12; N, 15.46. Found: C, 69.78; H, 6.36; N, 15.78.</p></sec><sec id="Sec38"><title>2-(Pyrrolidin-1-ylmethyl)-3-[(3,4,5-trimethoxybenzylidene)amino]quinazolin-4(3<italic>H</italic>)-one (19)</title><p id="Par58">White solid, m.p. 166&#x000a0;&#x000b0;C, yield 80%, HPLC: purity 99.36%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;4.04&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1676 (C=O), 1600 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.82 (s, 1H), 8.31 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x000a0;Hz, 1H), 7.77 (dt, <italic>J</italic>&#x02009;=&#x02009;16.4, 4.8&#x000a0;Hz, 2H), 7.53 &#x02013; 7.45 (m, 1H), 7.16 (s, 2H), 3.96 (s, 5H), 3.95 (s, 6H), 2.80 (br s, 4H), 1.83 (br s, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 167.81, 158.68, 153.57, 152.59, 146.31, 142.01, 134.14, 127.82, 127.75, 127.06, 126.75, 121.61, 106.07, 61.04, 57.61, 56.28, 54.31, 23.70. MS (EI) <italic>m/z</italic> (%): 423.33 (M<sup>+</sup> &#x02009;+&#x02009;1, 3.12). Anal. calcd. for C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>: C, 65.39; H, 6.20; N, 13.26. Found: C, 65.52; H, 6.46; N, 13.49.</p></sec><sec id="Sec39"><title>3-[(4-Nitrobenzylidene)amino]-2-(pyrrolidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (20)</title><p id="Par59">Yellow solid, m.p. 156&#x000a0;&#x000b0;C, yield 70%, HPLC: purity 98.96%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;6.29&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1676 (C=O), 1616 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 9.27 (s, 1H), 8.29 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 8.23 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x000a0;Hz, 1H), 7.99 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 7.71 (q, <italic>J</italic>&#x02009;=&#x02009;8.1&#x000a0;Hz, 2H), 7.46 &#x02013; 7.38 (m, 1H), 3.91 (s, 2H), 2.68 (s, 4H), 1.73 (s, 4H). <sup>13</sup>C NMR (100&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 162.74, 158.98, 153.03, 149.85, 146.10, 138.90, 134.53, 129.36, 127.93, 127.20, 127.03, 124.16, 121.58, 58.09, 54.42, 23.68. MS (EI) <italic>m/z</italic> (%): 377.34 (M<sup>+</sup>, 7.5). Anal. calcd. for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>: C, 63.65; H, 5.07; N, 18.56. Found: C, 63.91; H, 5.32; N, 18.89.</p></sec><sec id="Sec40"><title>3-(Benzylideneamino)-2-(piperidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (21)</title><p id="Par60">White solid, m.p. 98&#x000a0;&#x000b0;C, yield 75%, HPLC: purity 97.36%, R<sub>t</sub>&#x02009;=&#x02009;6.47&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1678 (C=O), 1601 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.50 (s, 1H), 8.30 (s, 1H), 7.91 (d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x000a0;Hz, 2H), 7.41 &#x02013; 7.56 (m, 6H), 3.08 (s, 2H), 2.51 (br s, 4H), 1.32 (d, <italic>J</italic>&#x02009;=&#x02009;12&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 164.68, 158.65, 149.03, 137.67, 134.22, 132.65, 131.84, 130.45, 128.66, 127.65, 123.22, 122.52, 122.02, 63.03, 55.03, 25.60, 23.72. MS (EI) m/z (%): 346.9 (M<sup>+</sup>, 9.9). Anal. calcd. for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O: C, 72.81; H, 6.40; N, 16.17. Found: C, 73.14; H, 6.72; N, 16.38.</p></sec><sec id="Sec41"><title>3-[(4-Chlorobenzylidene)amino]-2-(piperidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (22)</title><p id="Par61">White solid, m.p. 130&#x000a0;&#x000b0;C, yield 79%, HPLC: purity 95.27%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;4.43&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1675 (C=O), 1602 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.83 (s, 1H), 8.32 (d, <italic>J</italic>&#x02009;=&#x02009;8.4&#x000a0;Hz, 1H), 7.88 (d, <italic>J</italic>&#x02009;=&#x02009;8.9&#x000a0;Hz, 2H), 7.78 (d, <italic>J</italic>&#x02009;=&#x02009;8.5&#x000a0;Hz, 2H), 7.50 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 3H), 3.71 (s, 2H), 2.56 (br s, 4H), 1.42 (d, <italic>J</italic>&#x02009;=&#x02009;14.7&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 167.81, 158.56, 151.99, 146.21, 138.66, 134.14, 131.21, 130.00, 129.32, 127.67, 127.09, 126.83, 121.76, 61.13, 54.51, 25.79, 23.93. MS (EI) <italic>m/z</italic> (%): 380.83 (M<sup>+</sup>, 1.48). Anal. calcd. for C<sub>21</sub>H<sub>21</sub>ClN<sub>4</sub>O: C, 66.22; H, 5.56; N, 14.71. Found: C, 66.51; H, 5.77; N, 14.97.</p></sec><sec id="Sec42"><title>3-[(4-Methylbenzylidene)amino]-2-(piperidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (23)</title><p id="Par62">White solid, m.p. 124&#x000a0;&#x000b0;C, yield 75%, HPLC: purity 98.79%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;6.73&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1676 (C=O), 1604 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.73 (s, 1H), 8.33 (d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x000a0;Hz, 1H), 7.82 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x000a0;Hz, 2H), 7.80 &#x02013; 7.71 (m, 2H), 7.54 &#x02013;7.45 (m, 1H), 7.32 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x000a0;Hz, 2H), 3.70 (s, 2H), 2.55 (br s, 4H), 2.45 (s, 3H), 1.41 (d, <italic>J</italic>&#x02009;=&#x02009;20.9&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 169.78, 158.61, 152.03, 146.32, 143.24, 133.95, 129.94, 129.66, 128.94, 127.62, 127.04, 126.66, 121.84, 60.79, 54.51, 25.77, 23.97, 21.77. MS (EI) <italic>m/z</italic> (%): 361.16 (M<sup>+</sup> &#x02009;+&#x02009;1, 3). Anal. calcd. for C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>O: C, 73.31; H, 6.71; N, 15.54. Found: C, 73.65; H, 6.89; N, 15.81.</p></sec><sec id="Sec43"><title>3-[(4-Methoxylbenzylidene)amino]-2-(piperidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (24)</title><p id="Par63">White solid, m.p. 138&#x000a0;&#x000b0;C, yield 84%, HPLC: purity 100%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;5.16&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1674 (C=O), 1598 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.65 (s, 1H), 8.32 (d, <italic>J</italic>&#x02009;=&#x02009;7.7&#x000a0;Hz, 1H), 7.88 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 7.80 &#x02013; 7.70 (m, 2H), 7.53 &#x02013; 7.44 (m, 1H), 7.01 (d, <italic>J</italic>&#x02009;=&#x02009;8.8&#x000a0;Hz, 2H), 3.90 (s, 3H), 3.68 (s, 2H), 2.54 (br s, 4H), 1.41 (d, <italic>J</italic>&#x02009;=&#x02009;19.4&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 169.49, 163.18, 158.67, 152.42, 146.35, 133.90, 130.81, 127.59, 127.00, 126.67, 125.24, 121.84, 114.37, 60.95, 55.46, 54.50, 25.78, 23.97. MS (EI) <italic>m/z</italic> (%): 376.55 (M<sup>+</sup>, 6.15). Anal. calcd. for C<sub>22</sub>H<sub>24</sub>N<sub>4</sub>O<sub>2</sub>: C, 70.19; H, 6.43; N, 14.88. Found: C, 70.35; H, 6.81; N, 14.96.</p></sec><sec id="Sec44"><title>2-(Piperidin-1-ylmethyl)-3-[(3,4,5-trimethoxybenzylidene)amino]quinazolin-4(3<italic>H</italic>)-one (25)</title><p id="Par64">White solid, m.p. 112&#x02013;114&#x000a0;&#x000b0;C, yield 75%, HPLC: purity 97.90%, R<sub>t</sub>&#x02009;=&#x02009;3.98&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 16,714 (C=O), 1602 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.69 (s, 1H), 8.31 (d, <italic>J</italic>&#x02009;=&#x02009;7.8&#x000a0;Hz, 1H), 7.76 (s, 2H), 7.54 &#x02013;7.44 (m, 1H), 7.17 (s, 2H), 3.95 (s, 3H), 3.93 (s, 6H), 3.70 (s, 2H), 2.57 (s, 4H), 1.43 (d, <italic>J</italic>&#x02009;=&#x02009;27.0&#x000a0;Hz, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 169.18, 158.64, 153.53, 146.24, 142.00, 134.06, 127.79, 127.63, 127.04, 126.77, 121.75, 61.03, 56.28, 54.56, 25.82, 23.95. MS (EI) m/z (%): 436.79 (M<sup>+</sup>, 10.49). Anal. calcd. for C<sub>24</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>: C, 66.04; H, 6.47; N, 12.84. Found: C, 66.33; H, 6.62; N, 13.13.</p></sec><sec id="Sec45"><title>3-[4-Nitrobenzylidene)amino]-2-(piperidin-1-ylmethyl)quinazolin-4(3<italic>H</italic>)-one (26)</title><p id="Par65">Yellow solid, m.p. 180&#x02013;182&#x000a0;&#x000b0;C, yield 75%, HPLC: purity 100%, <italic>R</italic><sub>t</sub>&#x02009;=&#x02009;4.06&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1679 (C=O), 1612 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 9.13 (s, 1H), 8.37 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x000a0;Hz, 2H), 8.31 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x000a0;Hz, 1H), 8.10 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x000a0;Hz, 2H), 7.78 (d, <italic>J</italic>&#x02009;=&#x02009;3.2&#x000a0;Hz, 2H), 7.52 (dd, <italic>J</italic>&#x02009;=&#x02009;9.8, 6.5&#x000a0;Hz, 1H), 3.73 (s, 2H), 2.54 (s, 4H), 1.54 &#x02013; 1.30 (m, 6H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 164.78, 158.66, 152.36, 149.89, 146.06, 138.69, 134.44, 129.39, 127.77, 127.19, 127.05, 124.12, 121.67, 61.46, 54.60, 25.90, 23.95. MS (EI) m/z (%): 392.3 (M<sup>+</sup> &#x02009;+&#x02009;1, 1.3). Anal. calcd. for C<sub>21</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>: C, 64.44; H, 5.41; N, 17.89. Found: C, 64.67; H, 5.58; N, 18.22.</p></sec><sec id="Sec46"><title>3-(Benzylideneamino)-2-(morpholinomethyl)quinazolin-4(3<italic>H</italic>)-one (27)</title><p id="Par66">White solid, m.p. 132&#x000a0;&#x000b0;C, yield 71%, HPLC: purity 98.23%, R<sub>t</sub>&#x02009;=&#x02009;6.02&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1671 (C=O), 1594 (C=N). MS: for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>, calcd. 348.16, found 348.68 (M<sup>+</sup>). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.82 (s, 1H), 8.23 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x000a0;Hz, 1H), 7.83 (d, <italic>J</italic>&#x02009;=&#x02009;7.1&#x000a0;Hz, 2H), 7.68 (d, <italic>J</italic>&#x02009;=&#x02009;3.7&#x000a0;Hz, 2H), 7.53 &#x02013; 7.35 (m, 4H), 3.74 (s, 2H), 3.56 (br s, 4H), 2.63 (br s, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 168.66, 158.52, 151.64, 146.05, 134.23, 132.62, 128.95, 127.68, 127.09, 121.82, 66.65, 60.30, 53.54. MS (EI) m/z (%): 348.68 (M<sup>+</sup>, 45). Anal. calcd. for C<sub>20</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>: C, 68.95; H, 5.79; N, 16.08. Found: C, 69.28; H, 6.12; N, 16.35.</p></sec><sec id="Sec47"><title>3-[(4-Chlorobenzylidene)amino]-2-(morpholinomethyl)quinazolin-4(3<italic>H</italic>)-one (28)</title><p id="Par67">White solid, m.p. 140&#x02013;142&#x000a0;&#x000b0;C, yield 79%, HPLC: purity 99.35%, R<sub>t</sub>&#x02009;=&#x02009;3.73&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1677 (C=O), 1592 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.93 (s, 1H), 8.32 (m, 1H), 7.86 (m, 2H), 7.78 (m, 2H), 7.51 (m, 3H), 3.81 (s, 2H) 3.64 (t, 4H), 2.69 (s, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 167.03, 158.72, 151.53, 146.14, 138.97, 134.46, 131.23, 130.06, 129.57, 127.84, 127.31, 127.21, 121.86, 66.88, 60.61, 53.72. MS (EI) m/z (%): 383.10 (M<sup>+</sup> &#x02009;+&#x02009;1, 0.96). Anal. calcd. for C<sub>20</sub>H<sub>19</sub> ClN<sub>4</sub>O<sub>2</sub>: C, 62.75; H, 5.00; N, 14.63. Found: C, 63.12; H, 5.31; N, 14.88.</p></sec><sec id="Sec48"><title>3-[(4-Methylbenzylidene)amino]-2-(morpholinomethyl)quinazolin-4(3<italic>H</italic>)-one (29)</title><p id="Par68">White solid, m.p. 128&#x000a0;&#x000b0;C, yield 71%, HPLC: purity 100%, R<sub>t</sub>&#x02009;=&#x02009;7.74&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1671 (C=O), 1604 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.80 (s, 1H), 8.33 (m, 1H), 7.81 (m, 2H), 7.77 (m, 2H), 7.51 (m, 1H), 7.33 (d, <italic>J</italic>&#x02009;=&#x02009;8.0&#x000a0;Hz, 2H), 3.79 (s, 2H) 3.63 (t, 4H), 2.68 (s, 4H), 2.46 (s, 3H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 169.13, 158.61, 146.15, 143.51, 134.16, 129.79, 129.51, 128.91, 127.66, 127.13, 126.93, 121.82, 66.78, 60.43, 53.57. MS (EI) m/z (%): 363.27 (M<sup>+</sup> &#x02009;+&#x02009;1, 2.49). Anal. calcd. for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>: C, 69.59; H, 6.12; N, 15.46. Found: C, 69.81; H, 6.40; N, 15.65.</p></sec><sec id="Sec49"><title>3-[(4-Methoxylbenzylidene)amino]-2-(morpholinomethyl)quinazolin-4(3<italic>H</italic>)-one (30)</title><p id="Par69">White solid, m.p. 138&#x000a0;&#x000b0;C, yield 80%, HPLC: purity 96.59%, R<sub>t</sub>&#x02009;=&#x02009;3.39&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1672 (C=O), 1604 (C=N).<sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.70 (s, 1H), 8.30 (m, 1H), 7.85 (m, 2H), 7.74 (m, 2H), 7.49 (m, 1H), 7.0 (m, 2H), 3.98 (s, 3H) 3.75 (s, 2H), 3.60 (t, 4H), 2.65 (s, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 168.95, 163.42, 158.76, 146.29, 134.19, 130.91, 127.75, 127.21, 126.98, 125.20, 121.94, 114.61, 66.90, 60.55, 55.63, 53.68. MS (EI) m/z (%): 378.91 (M<sup>+</sup>, 3.9). Anal. calcd. for C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>: C, 66.65; H, 5.86; N, 14.81. Found: C, 66.91; H, 6.15; N, 15.15.</p></sec><sec id="Sec50"><title>2-(Morpholinomethyl)-3-[(3,4,5-trimethoxybenzylidene)amino]quinazolin-4(3<italic>H</italic>)-one (31)</title><p id="Par70">White solid, m.p. 155&#x000a0;&#x000b0;C, yield 78%, HPLC: purity 98.99%, R<sub>t</sub>&#x02009;=&#x02009;4.81&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1662 (C=O), 1575 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 8.73 (s, 1H), 8.30 (d, <italic>J</italic>&#x02009;=&#x02009;7.9&#x000a0;Hz, 1H), 7.75 (d, <italic>J</italic>&#x02009;=&#x02009;3.5&#x000a0;Hz, 2H), 7.53 &#x02013; 7.45 (m, 1H), 7.16 (s, 2H), 3.95 (s, 3H), 3.93 (s, 6H), 3.76 (s, 2H), 3.66 &#x02013; 3.59 (m, 4H), 2.66 (br s, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 168.82, 158.54, 153.60, 151.51, 146.12, 142.09, 134.17, 127.66, 127.10, 126.93, 121.72, 106.01, 66.85, 61.04, 60.57, 56.29, 53.63. MS (EI) m/z (%): 439.29 (M<sup>+</sup> &#x02009;+&#x02009;1, 15.9). Anal. calcd. for C<sub>23</sub>H<sub>26</sub>N<sub>4</sub>O<sub>5</sub>: C, 63.00; H, 5.98; N, 12.78. Found: C, 63.31; H, 6.21; N, 13.04.</p></sec><sec id="Sec51"><title>2-(Morpholinomethyl)-3-[(4-nitrobenzylidene)amino]quinazolin-4(3<italic>H</italic>)-one (32)</title><p id="Par71">Yellow solid, m.p. 200&#x000a0;&#x000b0;C, yield 68%, HPLC: purity 99.84%, R<sub>t</sub>&#x02009;=&#x02009;4.02&#x000a0;min. IR (KBr, cm<sup>&#x02212;1</sup>): 1672 (C=O), 1619 (C=N). <sup>1</sup>H NMR (400&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 9.18 (s, 1H), 8.29 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x000a0;Hz, 3H), 7.99 (d, <italic>J</italic>&#x02009;=&#x02009;8.7&#x000a0;Hz, 2H), 7.71 (d, <italic>J</italic>&#x02009;=&#x02009;6.1&#x000a0;Hz, 2H), 7.45 (t, <italic>J</italic>&#x02009;=&#x02009;7.0&#x000a0;Hz, 1H), 3.75 (s, 2H), 3.56 (s, 4H), 2.59 (s, 4H). <sup>13</sup>C NMR (101&#x000a0;MHz, CDCl<sub>3</sub>) &#x003b4; 163.61, 158.77, 151.76, 149.93, 145.86, 138.65, 134.61, 129.32, 127.84, 127.28, 124.22, 121.66, 66.86, 60.83, 53.72. MS (EI) m/z (%): 394.20 (M<sup>+</sup> &#x02009;+&#x02009;1, 1.93) Anal. calcd. for C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O<sub>4</sub>: C, 61.06; H, 4.87; N, 17.80. Found: C, 61.34; H, 5.14; N, 18.05.</p></sec></sec></sec></sec><sec id="Sec52"><title>In vitro studies</title><p id="Par72">This work has been granted the final approval of the Medical Research Ethics Committee (MREC) of the National Research Centre in Egypt after satisfying the guidelines and recommendations, under number R113010141.</p><sec id="Sec53"><title>Microorganisms</title><p id="Par73">The antimicrobial activity was tested against Gram positive bacteria: <italic>Bacillus cereus</italic> (<italic>B. cereus</italic> ATCC 6629), <italic>Bacillus subtilis</italic> (<italic>B. subtilis</italic> ATCC 6633), <italic>Staphylococcus aureus</italic> (<italic>S. aureus</italic> ATCC 6538), Gram negative bacteria: <italic>Klebsiella pneumoniae</italic> (<italic>K. pneumoniae</italic> ATCC 13883), <italic>Pseudomonas aeruginosa</italic> (<italic>P. aeruginosa</italic> ATCC 27953) and <italic>Candida albicans</italic> (<italic>C. albicans</italic> ATCC 10231). Glycerol stocks were thawed upon need and propagated into nutrient broth at 37&#x000a0;&#x000b0;C.</p></sec><sec id="Sec54"><title>Antimicrobial assay</title><p id="Par74">The antibacterial activity of the compounds<bold> 9</bold>&#x02013;<bold>32</bold> was carried out in vitro using the agar well diffusion method, originally reported by Heatley and Bauer and coworkers and described by the National Committee for Clinical Laboratory Standards (NCCLS) [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Bacterial strains, adjusted at 10<sup>6</sup>&#x000a0;cfu/ml (equivalent to 0.5 McFarland), were used to inoculate nutrient agar plates. 9-mm diameter wells were punched into the solidified nutrient agar plates using sterile cork borer and 100&#x000a0;&#x003bc;l samples of the test compounds, dissolved in dimethyl formamide (DMF) at 20&#x000a0;mg/ml concentrations, were added and allowed to diffuse at 4&#x000a0;&#x000b0;C for 2&#x000a0;h. Subsequently, the plates were incubated overnight in an upright position at 37&#x000a0;&#x000b0;C. DMF was used as a negative control while ciprofloxacin and fluconazole (30&#x000a0;&#x003bc;g/ml) served as positive controls. After 24&#x000a0;h incubation, the diameters of the growth inhibition zones were recorded in mm. Data was expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation of three replicates.</p></sec><sec id="Sec55"><title>Determination of minimum inhibitory concentration (MIC)</title><p id="Par75">Serial dilutions of the test compounds were tested to determine their MIC against the most susceptible organisms. The MIC was expressed as the lowest concentration which inhibited the visible growth of the corresponding microorganism. All assays were performed in triplicate.</p></sec></sec><sec id="Sec56"><title>In vitro cytotoxicity</title><p id="Par76">The most broad spectrum compounds were evaluated for their cytotoxic activity against BJ1 cell line using colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay [<xref ref-type="bibr" rid="CR71">71</xref>].</p><sec id="Sec57"><title>Biofilm assay</title><p id="Par77">Compounds with potential activity against <italic>P. aeruginosa</italic> ATCC 27953 were tested for the respective biofilm inhibition. The assay was carried out in microtiter plate setup using crystal violet (CV) staining of adherent cells, as modified from [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR64">64</xref>].</p><p id="Par78">Overnight cultures of <italic>P. aeruginosa</italic> were adjusted to optical density (OD<sub>600</sub>) of 0.2 and sub-cultured at 37&#x000a0;&#x000b0;C in 96-well microtiter plates with serial dilutions of compounds <bold>19</bold> and <bold>20</bold>, which span three orders of magnitude above and below the corresponding MIC. After 24&#x000a0;h cultivation, the supernatant and planktonic cells were discarded, wells were washed with phosphate buffered saline (PBS) and biofilms were stained with 0.1% CV. CV was subsequently washed then, solubilized with 33% (v/v) glacial acetic acid. The absorbance was measured at 540&#x000a0;nm using SPECTROstar&#x000ae; Nano microplate reader (BMG LABTECH GmbH, Germany). The experiments were performed in triplicate and independently repeated three times. GraphPad Prism 6.0 software was used to estimate the IC<sub>50</sub> values, which correspond to half the concentration required to obtain the maximum biofilm inhibition percentage.</p></sec><sec id="Sec58"><title>Bacterial cell surface hydrophobicity (CSH) assay</title><p id="Par79">The effect of the test compounds <bold>19</bold> and <bold>20</bold> on cell surface hydrophobicity was investigated via the microbial or bacterial adherence to hydrocarbons (MATH / BATH) assay [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Exponentially growing culture of <italic>P. aeruginosa</italic> ATCC 27953 incubated with or without test compounds were centrifuged, the pellets were re-suspended and OD<sub>600</sub> was measured using UV/Vis spectrophotometer (Jasco V-630, Tokyo, Japan) to give <italic>A</italic><sub><italic>o</italic></sub>. The re-suspended cells were vigorously mixed with toluene followed by measuring the OD<sub>600</sub> of the aqueous phase to give <italic>A</italic><sub><italic>t</italic></sub>. The hydrophobicity index was calculated as follows:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{Hydrophobicity\, index}=\frac{{A}_{o}-{A}_{t}}{{A}_{o}}\times 100$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Hydrophobicity</mml:mi><mml:mspace width="0.166667em"/><mml:mi mathvariant="normal">index</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mi>o</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>A</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mi>o</mml:mi></mml:msub></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math><graphic xlink:href="11030_2024_10830_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec59"><title>Inhibition of exopolysaccharide (EPS) production</title><p id="Par80">The inhibition of exopolysaccharide production by <italic>P. aeruginosa</italic> ATCC 27953 using quinazolinone derivatives was assessed according to total carbohydrate measurement [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR72">72</xref>].</p><p id="Par81"><italic>P. aeruginosa</italic>&#x02019;s biofilm was grown in the presence or absence of compounds (<bold>19, 20</bold>). Cells were incubated for 1&#x000a0;h with an equal volume of 5% (v/v) phenol and 5&#x02009;&#x000d7;&#x02009;volume of concentrated sulfuric acid containing 0.2% (w/v) hydrazine sulphate then centrifuged at 10,000&#x000a0;g for 10&#x000a0;min (Z 326&#x000a0;K, HERMLE Labortechnik GmbH, Wehingen, Germany). The optical density of the supernatant was measured at 490&#x000a0;nm and the reduction in EPS was calculated as follows:<disp-formula id="Equb"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathrm{EPS\, quantification\, }\left(\mathrm{\%}\right)= \frac{{{\text{OD}}}_{490\, }\mathrm{of\, control}-{{\text{OD}}}_{490\, }\mathrm{of\, test}}{{{\text{OD}}}_{490}\mathrm{ of\, control}} \times 100$$\end{document}</tex-math><mml:math id="M4" display="block"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">EPS</mml:mi><mml:mspace width="0.166667em"/><mml:mi mathvariant="normal">quantification</mml:mi><mml:mspace width="0.166667em"/></mml:mrow><mml:mfenced close=")" open="("><mml:mo>%</mml:mo></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mtext>OD</mml:mtext><mml:mrow><mml:mn>490</mml:mn><mml:mspace width="0.166667em"/></mml:mrow></mml:msub><mml:mrow><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.166667em"/><mml:mi mathvariant="normal">control</mml:mi></mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mtext>OD</mml:mtext><mml:mrow><mml:mn>490</mml:mn><mml:mspace width="0.166667em"/></mml:mrow></mml:msub><mml:mrow><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.166667em"/><mml:mi mathvariant="normal">test</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:msub><mml:mtext>OD</mml:mtext><mml:mn>490</mml:mn></mml:msub><mml:mrow><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.166667em"/><mml:mi mathvariant="normal">control</mml:mi></mml:mrow></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math><graphic xlink:href="11030_2024_10830_Article_Equb.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec60"><title>Twitching motility assay</title><p id="Par82">5 &#x000b5;L of overnight-grown bacteria were stab-inoculated into Luria Bertani (LB) soft or quasi-solid plates containing 0.3% agar mixed with different concentrations of compounds <bold>19</bold>, <bold>20</bold> and further incubated overnight in an upright position. The visible detectable distance of corrugated trails of twitching zones, away from the inoculation center at the petri dish-agar interface, was measured afterwards. The results were recorded as the average of several diameters&#x02019; measurements [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR73">73</xref>]. DMF was used as a negative control. The experiments were performed in triplicate and represented as the mean of three measurements.</p></sec><sec id="Sec61"><title>Molecular docking</title><p id="Par83">Molecular docking study was performed using discovery studio software 4.1. The 3D crystal structure of PqsR (PDB code: 6B8a), was downloaded from PDB followed by protein preparation and addition of hydrogen atoms. The binding site of the selected co-crystallized ligand (M64) was created as volumes. Before docking water molecules were omitted from the protein and the tested compounds were minimized energetically using CHARMm Force Field through ligand minimization tool. Docking was carried out using CDOCKER-CHARMm-based protocol. A maximum of 10 conformers was considered for each molecule in the docking analysis. After that the docking scores (CDOCKER interaction energy) of the best fitted conformation of each of the docked molecules with the amino acids at the LBD of PqsR were recorded.</p></sec></sec><sec id="Sec62" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11030_2024_10830_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 18947 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Rasha Mohamed Hassan and Heba Yehia are Co-first authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank the National Research Centre, Dokki, Giza, Egypt for supporting this work through the project no. 13010141. Also, we thanks Dr. Walaa Hamada Abd-Allah, Collage of Pharmaceutical Science and Drug Manufacturing, Misr University for Science and Technology for helping in molecular docking part.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>RMH and MFE contributed in the conceptualization of the idea of this study, carried out the synthesis and wrote the manuscript. HY performed all the microbiological tests and shared in the writing of the manuscript. AASE and MNA contributed in conceptualization of the idea and revised the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></notes><notes><title>Declarations</title><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par85">The authors do not have conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Gohary</surname><given-names>NS</given-names></name><name><surname>Shaaban</surname><given-names>MI</given-names></name></person-group><article-title>Antimicrobial and antiquorum-sensing studies. Part 3: synthesis and biological evaluation of new series of [1,3,4]thiadiazoles and fused [1,3,4]thiadiazoles</article-title><source>Arch Pharm</source><year>2015</year><volume>348</volume><fpage>283</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1002/ardp.201400381</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">El-Gohary NS, Shaaban MI (2015) Antimicrobial and antiquorum-sensing studies. Part 3: synthesis and biological evaluation of new series of [1,3,4]thiadiazoles and fused [1,3,4]thiadiazoles. Arch Pharm 348:283&#x02013;297. 10.1002/ardp.201400381</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Mor</surname><given-names>S</given-names></name><name><surname>Khatri</surname><given-names>M</given-names></name></person-group><article-title>Convenient synthesis of benzothiazinoisoindol-11-ones and benzoindenothiazin-11-ones, and antimicrobial testing thereof</article-title><source>Mol Divers</source><year>2023</year><volume>27</volume><fpage>1223</fpage><lpage>1241</lpage><pub-id pub-id-type="doi">10.1007/s11030-022-10483-9</pub-id><pub-id pub-id-type="pmid">35922654</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Mor S, Khatri M (2023) Convenient synthesis of benzothiazinoisoindol-11-ones and benzoindenothiazin-11-ones, and antimicrobial testing thereof. Mol Divers 27:1223&#x02013;1241. 10.1007/s11030-022-10483-9<pub-id pub-id-type="pmid">35922654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Reygaert</surname><given-names>WC</given-names></name></person-group><article-title>An overview of the antimicrobial resistance mechanisms of bacteria</article-title><source>AIMS Microbiol</source><year>2018</year><volume>4</volume><fpage>482</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.3934/microbiol.2018.3.482</pub-id><pub-id pub-id-type="pmid">31294229</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Reygaert WC (2018) An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol 4:482&#x02013;501. 10.3934/microbiol.2018.3.482<pub-id pub-id-type="pmid">31294229</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Ghwas</surname><given-names>DE</given-names></name><name><surname>Yehia</surname><given-names>H</given-names></name></person-group><article-title>Antibacterial efficiency of natural products against multiple-drug-resistant clinical isolates</article-title><source>Egypt Pharm J</source><year>2022</year><volume>21</volume><fpage>432</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.4103/epj.epj_48_22</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">El-Ghwas DE, Yehia H (2022) Antibacterial efficiency of natural products against multiple-drug-resistant clinical isolates. Egypt Pharm J 21:432&#x02013;439. 10.4103/epj.epj_48_22</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Vashistha</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Nanaji</surname><given-names>Y</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Barnwal</surname><given-names>RP</given-names></name><etal/></person-group><article-title>Quorum sensing inhibitors as therapeutics: bacterial biofilm inhibition</article-title><source>Bioorg Chem</source><year>2023</year><volume>136</volume><fpage>106551</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2023.106551</pub-id><pub-id pub-id-type="pmid">37094480</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Vashistha A, Sharma N, Nanaji Y, Kumar D, Singh G, Barnwal RP et al (2023) Quorum sensing inhibitors as therapeutics: bacterial biofilm inhibition. Bioorg Chem 136:106551. 10.1016/j.bioorg.2023.106551<pub-id pub-id-type="pmid">37094480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Hills</surname><given-names>OJ</given-names></name><name><surname>Yong</surname><given-names>CW</given-names></name><name><surname>Scott</surname><given-names>AJ</given-names></name><name><surname>Devine</surname><given-names>DA</given-names></name><name><surname>Smith</surname><given-names>J</given-names></name><name><surname>Chappell</surname><given-names>HF</given-names></name></person-group><article-title>Atomic-scale interactions between quorum sensing autoinducer molecules and the mucoid <italic>P. aeruginosa</italic> exopolysaccharide matrix</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><fpage>7724</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-11499-9</pub-id><pub-id pub-id-type="pmid">35545629</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Hills OJ, Yong CW, Scott AJ, Devine DA, Smith J, Chappell HF (2022) Atomic-scale interactions between quorum sensing autoinducer molecules and the mucoid <italic>P. aeruginosa</italic> exopolysaccharide matrix. Sci Rep 12:7724. 10.1038/s41598-022-11499-9<pub-id pub-id-type="pmid">35545629</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>SW</given-names></name><name><surname>Asfahl</surname><given-names>KL</given-names></name><name><surname>Dandekar</surname><given-names>AA</given-names></name><name><surname>Greenberg</surname><given-names>EP</given-names></name></person-group><article-title><italic>Pseudomonas aeruginosa</italic> quorum sensing</article-title><source>Adv Exp Med Biol</source><year>2022</year><volume>1386</volume><fpage>95</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1007/978-3-031-08491-1_4</pub-id><pub-id pub-id-type="pmid">36258070</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Miranda SW, Asfahl KL, Dandekar AA, Greenberg EP (2022) <italic>Pseudomonas aeruginosa</italic> quorum sensing. Adv Exp Med Biol 1386:95&#x02013;115. 10.1007/978-3-031-08491-1_4<pub-id pub-id-type="pmid">36258070</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Colvin</surname><given-names>KM</given-names></name><name><surname>Irie</surname><given-names>Y</given-names></name><name><surname>Tart</surname><given-names>CS</given-names></name><name><surname>Urbano</surname><given-names>R</given-names></name><name><surname>Whitney</surname><given-names>JC</given-names></name><name><surname>Ryder</surname><given-names>C</given-names></name><etal/></person-group><article-title>The Pel and Psl polysaccharides provide <italic>Pseudomonas aeruginosa</italic> structural redundancy within the biofilm matrix</article-title><source>Environ Microbiol</source><year>2012</year><volume>14</volume><fpage>1913</fpage><lpage>1928</lpage><pub-id pub-id-type="doi">10.1111/j.1462-2920.2011.02657.x</pub-id><pub-id pub-id-type="pmid">22176658</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Colvin KM, Irie Y, Tart CS, Urbano R, Whitney JC, Ryder C et al (2012) The Pel and Psl polysaccharides provide <italic>Pseudomonas aeruginosa</italic> structural redundancy within the biofilm matrix. Environ Microbiol 14:1913&#x02013;1928. 10.1111/j.1462-2920.2011.02657.x<pub-id pub-id-type="pmid">22176658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Boopathi</surname><given-names>S</given-names></name><name><surname>Vashisth</surname><given-names>R</given-names></name><name><surname>Manoharan</surname><given-names>P</given-names></name><name><surname>Kandasamy</surname><given-names>R</given-names></name><name><surname>Sivakumar</surname><given-names>N</given-names></name></person-group><article-title>Stigmatellin Y &#x02013; An anti-biofilm compound from <italic>Bacillus subtilis</italic> BR4 possibly interferes in PQS&#x02013;PqsR mediated quorum sensing system in <italic>Pseudomonas aeruginosa</italic></article-title><source>Bioorg Med Chem Lett</source><year>2017</year><volume>27</volume><fpage>2113</fpage><lpage>2118</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2017.03.074</pub-id><pub-id pub-id-type="pmid">28389154</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Boopathi S, Vashisth R, Manoharan P, Kandasamy R, Sivakumar N (2017) Stigmatellin Y &#x02013; An anti-biofilm compound from <italic>Bacillus subtilis</italic> BR4 possibly interferes in PQS&#x02013;PqsR mediated quorum sensing system in <italic>Pseudomonas aeruginosa</italic>. Bioorg Med Chem Lett 27:2113&#x02013;2118. 10.1016/j.bmcl.2017.03.074<pub-id pub-id-type="pmid">28389154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Bishai</surname><given-names>W</given-names></name><name><surname>Lesic</surname><given-names>B</given-names></name><name><surname>L&#x000e9;pine</surname><given-names>F</given-names></name><name><surname>D&#x000e9;ziel</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Inhibitors of pathogen intercellular signals as selective anti-infective compounds</article-title><source>PLoS Pathog</source><year>2007</year><volume>3</volume><fpage>e126</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.0030126</pub-id><pub-id pub-id-type="pmid">17941706</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Bishai W, Lesic B, L&#x000e9;pine F, D&#x000e9;ziel E, Zhang J, Zhang Q et al (2007) Inhibitors of pathogen intercellular signals as selective anti-infective compounds. PLoS Pathog 3:e126. 10.1371/journal.ppat.0030126<pub-id pub-id-type="pmid">17941706</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Emerson</surname><given-names>J</given-names></name><name><surname>Rosenfeld</surname><given-names>M</given-names></name><name><surname>McNamara</surname><given-names>S</given-names></name><name><surname>Ramsey</surname><given-names>B</given-names></name><name><surname>Gibson</surname><given-names>RL</given-names></name></person-group><article-title>Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis</article-title><source>Pediatr Pulmonol</source><year>2002</year><volume>34</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1002/ppul.10127</pub-id><pub-id pub-id-type="pmid">12112774</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL (2002) Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:91&#x02013;100. 10.1002/ppul.10127<pub-id pub-id-type="pmid">12112774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>Z</given-names></name><name><surname>Raudonis</surname><given-names>R</given-names></name><name><surname>Glick</surname><given-names>BR</given-names></name><name><surname>Lin</surname><given-names>T-J</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name></person-group><article-title>Antibiotic resistance in <italic>Pseudomonas aeruginosa</italic>: mechanisms and alternative therapeutic strategies</article-title><source>Biotechnol Adv</source><year>2019</year><volume>37</volume><fpage>177</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2018.11.013</pub-id><pub-id pub-id-type="pmid">30500353</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Pang Z, Raudonis R, Glick BR, Lin T-J, Cheng Z (2019) Antibiotic resistance in <italic>Pseudomonas aeruginosa</italic>: mechanisms and alternative therapeutic strategies. Biotechnol Adv 37:177&#x02013;192. 10.1016/j.biotechadv.2018.11.013<pub-id pub-id-type="pmid">30500353</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K-M</given-names></name><name><surname>Yoon</surname><given-names>MY</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>J-H</given-names></name><name><surname>Yoon</surname><given-names>SS</given-names></name><name><surname>McCormick</surname><given-names>BA</given-names></name></person-group><article-title>Anaerobiosis-induced loss of cytotoxicity is due to inactivation of quorum sensing in <italic>Pseudomonas aeruginosa</italic></article-title><source>Infect Immun</source><year>2011</year><volume>79</volume><fpage>2792</fpage><lpage>2800</lpage><pub-id pub-id-type="doi">10.1128/iai.01361-10</pub-id><pub-id pub-id-type="pmid">21555402</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Lee K-M, Yoon MY, Park Y, Lee J-H, Yoon SS, McCormick BA (2011) Anaerobiosis-induced loss of cytotoxicity is due to inactivation of quorum sensing in <italic>Pseudomonas aeruginosa</italic>. Infect Immun 79:2792&#x02013;2800. 10.1128/iai.01361-10<pub-id pub-id-type="pmid">21555402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Soheili</surname><given-names>V</given-names></name><name><surname>Tajani</surname><given-names>AS</given-names></name><name><surname>Ghodsi</surname><given-names>R</given-names></name><name><surname>Bazzaz</surname><given-names>BSF</given-names></name></person-group><article-title>Anti-PqsR compounds as next-generation antibacterial agents against <italic>Pseudomonas aeruginosa</italic>: a review</article-title><source>Euro J Med Chem</source><year>2019</year><volume>172</volume><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.03.049</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Soheili V, Tajani AS, Ghodsi R, Bazzaz BSF (2019) Anti-PqsR compounds as next-generation antibacterial agents against <italic>Pseudomonas aeruginosa</italic>: a review. Euro J Med Chem 172:26&#x02013;35. 10.1016/j.ejmech.2019.03.049</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Dewangan</surname><given-names>D</given-names></name><name><surname>Nakhate</surname><given-names>KT</given-names></name><name><surname>Verma</surname><given-names>VS</given-names></name><name><surname>Nagori</surname><given-names>K</given-names></name><name><surname>Tripathi</surname><given-names>DK</given-names></name></person-group><article-title>Synthesis, characterization, and screening for analgesic and anti-inflammatory activities of Schiff Bases of 1,3,4-oxadiazoles linked with quinazolin-4-one</article-title><source>J Heterocycl Chem</source><year>2017</year><volume>54</volume><fpage>3187</fpage><lpage>3194</lpage><pub-id pub-id-type="doi">10.1002/jhet.2934</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Dewangan D, Nakhate KT, Verma VS, Nagori K, Tripathi DK (2017) Synthesis, characterization, and screening for analgesic and anti-inflammatory activities of Schiff Bases of 1,3,4-oxadiazoles linked with quinazolin-4-one. J Heterocycl Chem 54:3187&#x02013;3194. 10.1002/jhet.2934</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Rajput</surname><given-names>CS</given-names></name></person-group><article-title>Synthesis and anti-inflammatory activity of newer quinazolin-4-one derivatives</article-title><source>Euro J Med Chem</source><year>2009</year><volume>44</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2008.03.018</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kumar A, Rajput CS (2009) Synthesis and anti-inflammatory activity of newer quinazolin-4-one derivatives. Euro J Med Chem 44:83&#x02013;90. 10.1016/j.ejmech.2008.03.018</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Mokale</surname><given-names>SN</given-names></name><name><surname>Palkar</surname><given-names>AD</given-names></name><name><surname>Dube</surname><given-names>PN</given-names></name><name><surname>Sakle</surname><given-names>NS</given-names></name><name><surname>Miniyar</surname><given-names>PB</given-names></name></person-group><article-title>Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents</article-title><source>Bioorg Med Chem Lett</source><year>2016</year><volume>26</volume><fpage>272</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2015.12.037</pub-id><pub-id pub-id-type="pmid">26707395</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Mokale SN, Palkar AD, Dube PN, Sakle NS, Miniyar PB (2016) Design, synthesis and in vivo screening of some novel quinazoline analogs as anti-hyperlipidemic and hypoglycemic agents. Bioorg Med Chem Lett 26:272&#x02013;276. 10.1016/j.bmcl.2015.12.037<pub-id pub-id-type="pmid">26707395</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>RM</given-names></name><name><surname>Ali</surname><given-names>IH</given-names></name><name><surname>Abdel-Maksoud</surname><given-names>MS</given-names></name><name><surname>Abdallah</surname><given-names>HMI</given-names></name><name><surname>El Kerdawy</surname><given-names>AM</given-names></name><name><surname>Sciandra</surname><given-names>F</given-names></name><etal/></person-group><article-title>Design and synthesis of novel quinazolinone-based fibrates as PPAR alpha agonists with antihyperlipidemic activity</article-title><source>Arch Pharm</source><year>2022</year><volume>355</volume><fpage>e2100399</fpage><pub-id pub-id-type="doi">10.1002/ardp.202100399</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Hassan RM, Ali IH, Abdel-Maksoud MS, Abdallah HMI, El Kerdawy AM, Sciandra F et al (2022) Design and synthesis of novel quinazolinone-based fibrates as PPAR alpha agonists with antihyperlipidemic activity. Arch Pharm 355:e2100399. 10.1002/ardp.202100399</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghorab</surname><given-names>MM</given-names></name><name><surname>Alsaid</surname><given-names>MS</given-names></name><name><surname>Soliman</surname><given-names>AM</given-names></name></person-group><article-title>Dual EGFR/HER2 inhibitors and apoptosis inducers: new benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers</article-title><source>Bioorg Chem</source><year>2018</year><volume>80</volume><fpage>611</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2018.07.015</pub-id><pub-id pub-id-type="pmid">30041137</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ghorab MM, Alsaid MS, Soliman AM (2018) Dual EGFR/HER2 inhibitors and apoptosis inducers: new benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers. Bioorg Chem 80:611&#x02013;620. 10.1016/j.bioorg.2018.07.015<pub-id pub-id-type="pmid">30041137</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Soliman</surname><given-names>AM</given-names></name><name><surname>Ghorab</surname><given-names>MM</given-names></name></person-group><article-title>Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents</article-title><source>Bioorg Chem</source><year>2019</year><volume>88</volume><fpage>102956</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2019.102956</pub-id><pub-id pub-id-type="pmid">31054432</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Soliman AM, Ghorab MM (2019) Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents. Bioorg Chem 88:102956. 10.1016/j.bioorg.2019.102956<pub-id pub-id-type="pmid">31054432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>IH</given-names></name><name><surname>Abdel-Mohsen</surname><given-names>HT</given-names></name><name><surname>Mounier</surname><given-names>MM</given-names></name><name><surname>Abo-Elfadl</surname><given-names>MT</given-names></name><name><surname>El Kerdawy</surname><given-names>AM</given-names></name><name><surname>Ghannam</surname><given-names>IAY</given-names></name></person-group><article-title>Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors</article-title><source>Bioorg Chem</source><year>2022</year><volume>126</volume><fpage>105883</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2022.105883</pub-id><pub-id pub-id-type="pmid">35636123</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ali IH, Abdel-Mohsen HT, Mounier MM, Abo-Elfadl MT, El Kerdawy AM, Ghannam IAY (2022) Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors. Bioorg Chem 126:105883. 10.1016/j.bioorg.2022.105883<pub-id pub-id-type="pmid">35636123</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x00142;owacka</surname><given-names>IE</given-names></name><name><surname>Grzonkowski</surname><given-names>P</given-names></name><name><surname>Lisiecki</surname><given-names>P</given-names></name><name><surname>Kalinowski</surname><given-names>&#x00141;</given-names></name><name><surname>Piotrowska</surname><given-names>DG</given-names></name></person-group><article-title>Synthesis and antimicrobial activity of novel 1,2,3-triazole-conjugates of quinazolin-4-ones</article-title><source>Arch Pharm</source><year>2019</year><volume>352</volume><fpage>1800302</fpage><pub-id pub-id-type="doi">10.1002/ardp.201800302</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">G&#x00142;owacka IE, Grzonkowski P, Lisiecki P, Kalinowski &#x00141;, Piotrowska DG (2019) Synthesis and antimicrobial activity of novel 1,2,3-triazole-conjugates of quinazolin-4-ones. Arch Pharm 352:1800302. 10.1002/ardp.201800302</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Gatadi</surname><given-names>S</given-names></name><name><surname>Lakshmi</surname><given-names>TV</given-names></name><name><surname>Nanduri</surname><given-names>S</given-names></name></person-group><article-title>4(3H)-Quinazolinone derivatives: Promising antibacterial drug leads</article-title><source>Euro J Med Chem</source><year>2019</year><volume>170</volume><fpage>157</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.03.018</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Gatadi S, Lakshmi TV, Nanduri S (2019) 4(3H)-Quinazolinone derivatives: Promising antibacterial drug leads. Euro J Med Chem 170:157&#x02013;172. 10.1016/j.ejmech.2019.03.018</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>N</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Bao</surname><given-names>X</given-names></name></person-group><article-title>Design, synthesis, crystal structure and in vitro antimicrobial activity of novel 1,2,4-triazolo[1,5-a]pyrimidine-containing quinazolinone derivatives</article-title><source>Mol Divers</source><year>2020</year><volume>25</volume><fpage>711</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1007/s11030-020-10043-z</pub-id><pub-id pub-id-type="pmid">32006295</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Du H, Ding M, Luo N, Shi J, Huang J, Bao X (2020) Design, synthesis, crystal structure and in vitro antimicrobial activity of novel 1,2,4-triazolo[1,5-a]pyrimidine-containing quinazolinone derivatives. Mol Divers 25:711&#x02013;722. 10.1007/s11030-020-10043-z<pub-id pub-id-type="pmid">32006295</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar Pandey</surname><given-names>S</given-names></name><name><surname>Yadava</surname><given-names>U</given-names></name><name><surname>Upadhyay</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>ML</given-names></name></person-group><article-title>Synthesis, biological evaluation and molecular docking studies of novel quinazolinones as antitubercular and antimicrobial agents</article-title><source>Bioorg Chem</source><year>2021</year><volume>108</volume><fpage>104611</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2020.104611</pub-id><pub-id pub-id-type="pmid">33484939</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kumar Pandey S, Yadava U, Upadhyay A, Sharma ML (2021) Synthesis, biological evaluation and molecular docking studies of novel quinazolinones as antitubercular and antimicrobial agents. Bioorg Chem 108:104611. 10.1016/j.bioorg.2020.104611<pub-id pub-id-type="pmid">33484939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>KC</given-names></name><name><surname>Dandia</surname><given-names>A</given-names></name><name><surname>Khanna</surname><given-names>S</given-names></name></person-group><article-title>Synthesis of some new fluorine containing bioactive heterocycles derived from fluorinated isatins and evaluation of the anti-bacterial activity</article-title><source>Indian J Chem&#x02014;B Org Med Chem</source><year>1992</year><volume>31</volume><fpage>105</fpage><lpage>1088</lpage></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Joshi KC, Dandia A, Khanna S (1992) Synthesis of some new fluorine containing bioactive heterocycles derived from fluorinated isatins and evaluation of the anti-bacterial activity. Indian J Chem&#x02014;B Org Med Chem 31:105&#x02013;1088</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Sahu</surname><given-names>SK</given-names></name><name><surname>Afzal</surname><given-names>A</given-names></name><name><surname>Banerjee</surname><given-names>M</given-names></name><name><surname>Acharrya</surname><given-names>S</given-names></name><name><surname>Behera</surname><given-names>CC</given-names></name><name><surname>Si</surname><given-names>S</given-names></name></person-group><article-title>Synthesis, characterization and biological activity of 2-methyl-3-aminoquinazolin-4(3H)-ones Schiff Bases</article-title><source>J Braz Chem Soc</source><year>2008</year><volume>19</volume><fpage>963</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1590/S0103-50532008000500023</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Sahu SK, Afzal A, Banerjee M, Acharrya S, Behera CC, Si S (2008) Synthesis, characterization and biological activity of 2-methyl-3-aminoquinazolin-4(3H)-ones Schiff Bases. J Braz Chem Soc 19:963&#x02013;970. 10.1590/S0103-50532008000500023</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>P</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Miao</surname><given-names>Z</given-names></name><name><surname>Ren</surname><given-names>D</given-names></name><etal/></person-group><article-title>An efficient nano CuO-catalyzed synthesis and biological evaluation of quinazolinone Schiff base derivatives and bis-2,3-dihydroquinazolin-4(1H)-ones as potent antibacterial agents against <italic>Streptococcus lactis</italic></article-title><source>Tetrahedron Lett</source><year>2016</year><volume>57</volume><fpage>5271</fpage><lpage>5277</lpage><pub-id pub-id-type="doi">10.1016/j.tetlet.2016.10.047</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zhang J, Cheng P, Ma Y, Liu J, Miao Z, Ren D et al (2016) An efficient nano CuO-catalyzed synthesis and biological evaluation of quinazolinone Schiff base derivatives and bis-2,3-dihydroquinazolin-4(1H)-ones as potent antibacterial agents against <italic>Streptococcus lactis</italic>. Tetrahedron Lett 57:5271&#x02013;5277. 10.1016/j.tetlet.2016.10.047</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Rasapalli</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>ZF</given-names></name><name><surname>Sammeta</surname><given-names>VR</given-names></name><name><surname>Golen</surname><given-names>JA</given-names></name><name><surname>Weig</surname><given-names>AW</given-names></name><name><surname>Melander</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Synthesis and biofilm inhibition studies of 2-(2-amino-6-arylpyrimidin-4-yl)quinazolin-4(3H)-ones</article-title><source>Bioorg Med Chem Lett</source><year>2020</year><volume>30</volume><fpage>127550</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127550</pub-id><pub-id pub-id-type="pmid">32927027</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Rasapalli S, Murphy ZF, Sammeta VR, Golen JA, Weig AW, Melander RJ et al (2020) Synthesis and biofilm inhibition studies of 2-(2-amino-6-arylpyrimidin-4-yl)quinazolin-4(3H)-ones. Bioorg Med Chem Lett 30:127550. 10.1016/j.bmcl.2020.127550<pub-id pub-id-type="pmid">32927027</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>SA</given-names></name><name><surname>Deshmukh</surname><given-names>SU</given-names></name><name><surname>Patil</surname><given-names>RB</given-names></name><name><surname>Damale</surname><given-names>MG</given-names></name><name><surname>Patil</surname><given-names>RH</given-names></name><name><surname>Alkahtani</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Identification of promising biofilm inhibitory and cytotoxic quinazolin-4-one derivatives: synthesis, evaluation, molecular docking and ADMET studies</article-title><source>ChemistrySelect</source><year>2019</year><volume>4</volume><fpage>3559</fpage><lpage>3566</lpage><pub-id pub-id-type="doi">10.1002/slct.201803795</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ansari SA, Deshmukh SU, Patil RB, Damale MG, Patil RH, Alkahtani HM et al (2019) Identification of promising biofilm inhibitory and cytotoxic quinazolin-4-one derivatives: synthesis, evaluation, molecular docking and ADMET studies. ChemistrySelect 4:3559&#x02013;3566. 10.1002/slct.201803795</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Ilangovan</surname><given-names>A</given-names></name><name><surname>Fletcher</surname><given-names>M</given-names></name><name><surname>Rampioni</surname><given-names>G</given-names></name><name><surname>Pustelny</surname><given-names>C</given-names></name><name><surname>Rumbaugh</surname><given-names>K</given-names></name><name><surname>Heeb</surname><given-names>S</given-names></name><etal/></person-group><article-title>Structural basis for native agonist and synthetic inhibitor recognition by the pseudomonas aeruginosa quorum sensing regulator PqsR (MvfR)</article-title><source>PLoS Pathog</source><year>2013</year><volume>9</volume><fpage>e1003508</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003508</pub-id><pub-id pub-id-type="pmid">23935486</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ilangovan A, Fletcher M, Rampioni G, Pustelny C, Rumbaugh K, Heeb S et al (2013) Structural basis for native agonist and synthetic inhibitor recognition by the pseudomonas aeruginosa quorum sensing regulator PqsR (MvfR). PLoS Pathog 9:e1003508. 10.1371/journal.ppat.1003508<pub-id pub-id-type="pmid">23935486</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Sabir</surname><given-names>S</given-names></name><name><surname>Das</surname><given-names>T</given-names></name><name><surname>Kuppusamy</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>TT</given-names></name><name><surname>Willcox</surname><given-names>MD</given-names></name><name><surname>Black</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Novel quinazolinone disulfide analogues as pqs quorum sensing inhibitors against <italic>Pseudomonas aeruginosa</italic></article-title><source>Bioorg Chem</source><year>2023</year><volume>130</volume><fpage>106226</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2022.106226</pub-id><pub-id pub-id-type="pmid">36332317</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Sabir S, Das T, Kuppusamy R, Yu TT, Willcox MD, Black DS et al (2023) Novel quinazolinone disulfide analogues as pqs quorum sensing inhibitors against <italic>Pseudomonas aeruginosa</italic>. Bioorg Chem 130:106226. 10.1016/j.bioorg.2022.106226<pub-id pub-id-type="pmid">36332317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Behairy</surname><given-names>MF</given-names></name><name><surname>Mazeed</surname><given-names>TE</given-names></name><name><surname>El-Azzouny</surname><given-names>AA</given-names></name><name><surname>Aboul-Enein</surname><given-names>MN</given-names></name></person-group><article-title>Design, synthesis and antibacterial potential of 5-(benzo[d][1,3]dioxol-5-yl)-3-tert-butyl-1-substituted-4,5-dihydropyrazoles</article-title><source>Saudi Pharm J</source><year>2015</year><volume>23</volume><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2014.07.009</pub-id><pub-id pub-id-type="pmid">25972742</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">El-Behairy MF, Mazeed TE, El-Azzouny AA, Aboul-Enein MN (2015) Design, synthesis and antibacterial potential of 5-(benzo[d][1,3]dioxol-5-yl)-3-tert-butyl-1-substituted-4,5-dihydropyrazoles. Saudi Pharm J 23:202&#x02013;209. 10.1016/j.jsps.2014.07.009<pub-id pub-id-type="pmid">25972742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>Z</given-names></name><name><surname>Kui</surname><given-names>C</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Kai</surname><given-names>L</given-names></name><name><surname>Qing</surname><given-names>J</given-names></name><name><surname>Hai</surname><given-names>Z</given-names></name></person-group><article-title>Synthesis of some N-alkyl substituted urea derivatives as antibacterial and antifungal agents</article-title><source>Eur J Med Chem</source><year>2010</year><volume>45</volume><fpage>3207</fpage><lpage>3212</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2010.03.027</pub-id><pub-id pub-id-type="pmid">20381216</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Qing Z, Kui C, Xiao Z, Kai L, Qing J, Hai Z (2010) Synthesis of some N-alkyl substituted urea derivatives as antibacterial and antifungal agents. Eur J Med Chem 45:3207&#x02013;3212. 10.1016/j.ejmech.2010.03.027<pub-id pub-id-type="pmid">20381216</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Gorrod</surname><given-names>JW</given-names></name><name><surname>Aislaitner</surname><given-names>G</given-names></name></person-group><article-title>The metabolism of alicyclic amines to reactive iminium ion intermediates</article-title><source>Eur J Drug Metab Pharmacokinet</source><year>1994</year><volume>19</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/BF03188923</pub-id><pub-id pub-id-type="pmid">7867663</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Gorrod JW, Aislaitner G (1994) The metabolism of alicyclic amines to reactive iminium ion intermediates. Eur J Drug Metab Pharmacokinet 19:209&#x02013;217. 10.1007/BF03188923<pub-id pub-id-type="pmid">7867663</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Harwood</surname><given-names>HJ</given-names></name><name><surname>Pyriadi</surname><given-names>TM</given-names></name></person-group><article-title>Use of acetyl chloride-triethylamine and acetic anhydride-triethylamine mixtures in the synthesis of isomaleimides from maleamic acids</article-title><source>J Org Chem</source><year>1971</year><volume>36</volume><fpage>821</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1021/jo00805a020</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Harwood HJ, Pyriadi TM (1971) Use of acetyl chloride-triethylamine and acetic anhydride-triethylamine mixtures in the synthesis of isomaleimides from maleamic acids. J Org Chem 36:821&#x02013;823. 10.1021/jo00805a020</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Sauter</surname><given-names>F</given-names></name><name><surname>Stanetty</surname><given-names>P</given-names></name><name><surname>Jordis</surname><given-names>U</given-names></name></person-group><article-title>Neue 3-Amino-chinazolinone</article-title><source>Arch Pharm</source><year>1977</year><volume>310</volume><fpage>680</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1002/ardp.19773100811</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Sauter F, Stanetty P, Jordis U (1977) Neue 3-Amino-chinazolinone. Arch Pharm 310:680&#x02013;682. 10.1002/ardp.19773100811</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>TS</given-names></name><name><surname>Bhatt</surname><given-names>JD</given-names></name><name><surname>Vanparia</surname><given-names>SF</given-names></name><name><surname>Patel</surname><given-names>UH</given-names></name><name><surname>Dixit</surname><given-names>RB</given-names></name><name><surname>Chudasama</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway</article-title><source>Bioorg Med Chem</source><year>2017</year><volume>25</volume><fpage>6635</fpage><lpage>6646</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2017.10.041</pub-id><pub-id pub-id-type="pmid">29126742</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Patel TS, Bhatt JD, Vanparia SF, Patel UH, Dixit RB, Chudasama CJ et al (2017) Ionic liquid mediated stereoselective synthesis of alanine linked hybrid quinazoline-4(3H)-one derivatives perturbing the malarial reductase activity in folate pathway. Bioorg Med Chem 25:6635&#x02013;6646. 10.1016/j.bmc.2017.10.041<pub-id pub-id-type="pmid">29126742</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>TS</given-names></name><name><surname>Bhatt</surname><given-names>JD</given-names></name><name><surname>Dixit</surname><given-names>RB</given-names></name><name><surname>Chudasama</surname><given-names>CJ</given-names></name><name><surname>Patel</surname><given-names>BD</given-names></name><name><surname>Dixit</surname><given-names>BC</given-names></name></person-group><article-title>Green synthesis, biological evaluation, molecular docking studies and 3D-QSAR analysis of novel phenylalanine linked quinazoline-4(3H)-one-sulphonamide hybrid entities distorting the malarial reductase activity in folate pathway</article-title><source>Bioorg Med Chem</source><year>2019</year><volume>27</volume><issue>16</issue><fpage>3574</fpage><lpage>3586</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2019.06.038</pub-id><pub-id pub-id-type="pmid">31272837</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Patel TS, Bhatt JD, Dixit RB, Chudasama CJ, Patel BD, Dixit BC (2019) Green synthesis, biological evaluation, molecular docking studies and 3D-QSAR analysis of novel phenylalanine linked quinazoline-4(3H)-one-sulphonamide hybrid entities distorting the malarial reductase activity in folate pathway. Bioorg Med Chem 27(16):3574&#x02013;3586. 10.1016/j.bmc.2019.06.038<pub-id pub-id-type="pmid">31272837</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>TS</given-names></name><name><surname>Vanparia</surname><given-names>SF</given-names></name><name><surname>Gandhi</surname><given-names>SA</given-names></name><name><surname>Patel</surname><given-names>UH</given-names></name><name><surname>Dixit</surname><given-names>RB</given-names></name><name><surname>Chudasama</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Novel stereoselective 2,3-disubstituted quinazoline-4(3H)-one derivatives derived from glycine as a potent antimalarial lead</article-title><source>New J Chem</source><year>2015</year><volume>39</volume><fpage>8638</fpage><lpage>8649</lpage><pub-id pub-id-type="doi">10.1039/c5nj01408e</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Patel TS, Vanparia SF, Gandhi SA, Patel UH, Dixit RB, Chudasama CJ et al (2015) Novel stereoselective 2,3-disubstituted quinazoline-4(3H)-one derivatives derived from glycine as a potent antimalarial lead. New J Chem 39:8638&#x02013;8649. 10.1039/c5nj01408e</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>TS</given-names></name><name><surname>Bhatt</surname><given-names>JD</given-names></name><name><surname>Dixit</surname><given-names>RB</given-names></name><name><surname>Chudasama</surname><given-names>CJ</given-names></name><name><surname>Patel</surname><given-names>BD</given-names></name><name><surname>Dixit</surname><given-names>BC</given-names></name></person-group><article-title>Design and synthesis of leucine-linked quinazoline-4(3H)-one-sulphonamide molecules distorting malarial reductase activity in the folate pathway</article-title><source>Arch Pharm</source><year>2019</year><volume>352</volume><fpage>1900099</fpage><pub-id pub-id-type="doi">10.1002/ardp.201900099</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Patel TS, Bhatt JD, Dixit RB, Chudasama CJ, Patel BD, Dixit BC (2019) Design and synthesis of leucine-linked quinazoline-4(3H)-one-sulphonamide molecules distorting malarial reductase activity in the folate pathway. Arch Pharm 352:1900099. 10.1002/ardp.201900099</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Vanparia</surname><given-names>SF</given-names></name><name><surname>Patel</surname><given-names>TS</given-names></name><name><surname>Dixit</surname><given-names>RB</given-names></name><name><surname>Dixit</surname><given-names>BC</given-names></name></person-group><article-title>Synthesis and in vitro antimicrobial activity of some newer quinazolinone&#x02013;sulfonamide linked hybrid heterocyclic entities derived from glycine</article-title><source>Med Chem Res</source><year>2013</year><volume>22</volume><fpage>5184</fpage><lpage>5196</lpage><pub-id pub-id-type="doi">10.1007/s00044-012-0320-7</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Vanparia SF, Patel TS, Dixit RB, Dixit BC (2013) Synthesis and in vitro antimicrobial activity of some newer quinazolinone&#x02013;sulfonamide linked hybrid heterocyclic entities derived from glycine. Med Chem Res 22:5184&#x02013;5196. 10.1007/s00044-012-0320-7</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Sharief</surname><given-names>AMS</given-names></name><name><surname>Ammar</surname><given-names>YA</given-names></name><name><surname>Zahran</surname><given-names>MA</given-names></name><name><surname>Ali</surname><given-names>AH</given-names></name><name><surname>El-Gaby</surname><given-names>MSA</given-names></name></person-group><article-title>Aminoacids in the synthesis of heterocyclic systems: the synthesis of triazinoquinazolinones, triazepinoquinazolinones and triazocinoquinazolinones of potential biological interest</article-title><source>Molecules</source><year>2001</year><volume>6</volume><fpage>267</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.3390/60300267</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">El-Sharief AMS, Ammar YA, Zahran MA, Ali AH, El-Gaby MSA (2001) Aminoacids in the synthesis of heterocyclic systems: the synthesis of triazinoquinazolinones, triazepinoquinazolinones and triazocinoquinazolinones of potential biological interest. Molecules 6:267&#x02013;278. 10.3390/60300267</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>J-F</given-names></name><name><surname>Cao</surname><given-names>L-H</given-names></name><name><surname>Wang</surname><given-names>D-Z</given-names></name><name><surname>Zhang</surname><given-names>J-B</given-names></name><name><surname>Zhou</surname><given-names>S-B</given-names></name><etal/></person-group><article-title>Synthesis of novel thioglycoside derivatives containing quinazolinone</article-title><source>J Chin Chem Soc</source><year>2009</year><volume>56</volume><fpage>419</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1002/jccs.200900062</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Huang H, Gao J-F, Cao L-H, Wang D-Z, Zhang J-B, Zhou S-B et al (2009) Synthesis of novel thioglycoside derivatives containing quinazolinone. J Chin Chem Soc 56:419&#x02013;424. 10.1002/jccs.200900062</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Hermecz</surname><given-names>I</given-names></name><name><surname>Szil&#x000e1;gyi</surname><given-names>I</given-names></name><name><surname>Orfi</surname><given-names>L</given-names></name><name><surname>K&#x000f6;k&#x000f6;si</surname><given-names>J</given-names></name><name><surname>Sz&#x000e1;sz</surname><given-names>G</given-names></name></person-group><article-title>Nitrogen bridgehead compounds: Part 85&#x02014;synthesis and reactivity of 3,4-dihydro-1H,6H[1,4]oxazino[3,4-b]quinazolin-6-ones</article-title><source>J Heterocycl Chem</source><year>1993</year><volume>30</volume><fpage>1413</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1002/jhet.5570300539</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Hermecz I, Szil&#x000e1;gyi I, Orfi L, K&#x000f6;k&#x000f6;si J, Sz&#x000e1;sz G (1993) Nitrogen bridgehead compounds: Part 85&#x02014;synthesis and reactivity of 3,4-dihydro-1H,6H[1,4]oxazino[3,4-b]quinazolin-6-ones. J Heterocycl Chem 30:1413&#x02013;1420. 10.1002/jhet.5570300539</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Fetter</surname><given-names>J</given-names></name><name><surname>Czuppon</surname><given-names>T</given-names></name><name><surname>Horny&#x000e1;k</surname><given-names>G</given-names></name><name><surname>Feller</surname><given-names>A</given-names></name></person-group><article-title>The synthesis of some 3-amino-2-halomethyl-, 2-halomethyl-3-(subst.amino)- and 2-halomethyl-3-hetarylquinazolin-4(3H)-ones as potential plant protecting agents</article-title><source>Tetrahedron</source><year>1991</year><volume>47</volume><fpage>9393</fpage><lpage>9410</lpage><pub-id pub-id-type="doi">10.1016/S0040-4020(01)80886-3</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Fetter J, Czuppon T, Horny&#x000e1;k G, Feller A (1991) The synthesis of some 3-amino-2-halomethyl-, 2-halomethyl-3-(subst.amino)- and 2-halomethyl-3-hetarylquinazolin-4(3H)-ones as potential plant protecting agents. Tetrahedron 47:9393&#x02013;9410. 10.1016/S0040-4020(01)80886-3</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Hofny</surname><given-names>HA</given-names></name><name><surname>Mohamed</surname><given-names>MFA</given-names></name><name><surname>Gomaa</surname><given-names>HAM</given-names></name><name><surname>Abdel-Aziz</surname><given-names>SA</given-names></name><name><surname>Youssif</surname><given-names>BGM</given-names></name><name><surname>El-Koussi</surname><given-names>NA</given-names></name><name><surname>Aboraia</surname><given-names>AS</given-names></name></person-group><article-title>Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV</article-title><source>Bioorg Chem</source><year>2021</year><volume>112</volume><fpage>104920</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2021.104920</pub-id><pub-id pub-id-type="pmid">33910078</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hofny HA, Mohamed MFA, Gomaa HAM, Abdel-Aziz SA, Youssif BGM, El-Koussi NA, Aboraia AS (2021) Design, synthesis, and antibacterial evaluation of new quinoline-1,3,4-oxadiazole and quinoline-1,2,4-triazole hybrids as potential inhibitors of DNA gyrase and topoisomerase IV. Bioorg Chem 112:104920. 10.1016/j.bioorg.2021.104920<pub-id pub-id-type="pmid">33910078</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>TS</given-names></name><name><surname>Almalki</surname><given-names>AJ</given-names></name><name><surname>Moustafa</surname><given-names>AH</given-names></name><name><surname>Allam</surname><given-names>RM</given-names></name><name><surname>Abuo-Rahma</surname><given-names>GEA</given-names></name><name><surname>El Subbagh</surname><given-names>HI</given-names></name><name><surname>Mohamed</surname><given-names>MFA</given-names></name></person-group><article-title>Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: design, synthesis, ADMET prediction and molecular docking study</article-title><source>Bioorg Chem</source><year>2021</year><volume>111</volume><fpage>104885</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2021.104885</pub-id><pub-id pub-id-type="pmid">33838559</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Ibrahim TS, Almalki AJ, Moustafa AH, Allam RM, Abuo-Rahma GEA, El Subbagh HI, Mohamed MFA (2021) Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: design, synthesis, ADMET prediction and molecular docking study. Bioorg Chem 111:104885. 10.1016/j.bioorg.2021.104885<pub-id pub-id-type="pmid">33838559</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Karatan</surname><given-names>E</given-names></name><name><surname>Watnick</surname><given-names>P</given-names></name></person-group><article-title>Signals, regulatory networks, and materials that build and break bacterial biofilms</article-title><source>Microbiol Molecul Biol Rev</source><year>2009</year><volume>73</volume><fpage>310</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1128/MMBR.00041-08</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Karatan E, Watnick P (2009) Signals, regulatory networks, and materials that build and break bacterial biofilms. Microbiol Molecul Biol Rev 73:310&#x02013;347. 10.1128/MMBR.00041-08</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Vashistha</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Nanaji</surname><given-names>Y</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>G</given-names></name><name><surname>Barnwal</surname><given-names>RP</given-names></name><name><surname>Yadav</surname><given-names>AK</given-names></name></person-group><article-title>Quorum sensing inhibitors as therapeutics: bacterial biofilm inhibition</article-title><source>Bioorg Chem</source><year>2023</year><volume>136</volume><fpage>106551</fpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2023.106551</pub-id><pub-id pub-id-type="pmid">37094480</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Vashistha A, Sharma N, Nanaji Y, Kumar D, Singh G, Barnwal RP, Yadav AK (2023) Quorum sensing inhibitors as therapeutics: bacterial biofilm inhibition. Bioorg Chem 136:106551. 10.1016/j.bioorg.2023.106551<pub-id pub-id-type="pmid">37094480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Jayaraman</surname><given-names>N</given-names></name><name><surname>Chatterji</surname><given-names>D</given-names></name></person-group><article-title>Small-Molecule Inhibition of Bacterial Biofilm</article-title><source>ACS Omega</source><year>2020</year><volume>5</volume><fpage>3108</fpage><lpage>3115</lpage><pub-id pub-id-type="doi">10.1021/acsomega.9b03695</pub-id><pub-id pub-id-type="pmid">32118127</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Ghosh A, Jayaraman N, Chatterji D (2020) Small-Molecule Inhibition of Bacterial Biofilm. ACS Omega 5:3108&#x02013;3115. 10.1021/acsomega.9b03695<pub-id pub-id-type="pmid">32118127</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Shree</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>CK</given-names></name><name><surname>Sodhi</surname><given-names>KK</given-names></name><name><surname>Surya</surname><given-names>JN</given-names></name><name><surname>Singh</surname><given-names>DK</given-names></name></person-group><article-title>Biofilms: understanding the structure and contribution towards bacterial resistance in antibiotics</article-title><source>Med Microecol</source><year>2023</year><volume>16</volume><fpage>100084</fpage><pub-id pub-id-type="doi">10.1016/j.medmic.2023.100084</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Shree P, Singh CK, Sodhi KK, Surya JN, Singh DK (2023) Biofilms: understanding the structure and contribution towards bacterial resistance in antibiotics. Med Microecol 16:100084. 10.1016/j.medmic.2023.100084</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>RM</given-names></name><name><surname>Abd El-Maksoud</surname><given-names>MS</given-names></name><name><surname>Ghannam</surname><given-names>IAY</given-names></name><name><surname>El-Azzouny</surname><given-names>AA</given-names></name><name><surname>Aboul-Enein</surname><given-names>MN</given-names></name></person-group><article-title>Synthetic non-toxic anti-biofilm agents as a strategy in combating bacterial resistance</article-title><source>Eur J Med Chem</source><year>2023</year><volume>262</volume><fpage>115867</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115867</pub-id><pub-id pub-id-type="pmid">37866335</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Hassan RM, Abd El-Maksoud MS, Ghannam IAY, El-Azzouny AA, Aboul-Enein MN (2023) Synthetic non-toxic anti-biofilm agents as a strategy in combating bacterial resistance. Eur J Med Chem 262:115867. 10.1016/j.ejmech.2023.115867<pub-id pub-id-type="pmid">37866335</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Noori</surname><given-names>HG</given-names></name><name><surname>Tadjrobehkar</surname><given-names>O</given-names></name><name><surname>Moazamian</surname><given-names>E</given-names></name></person-group><article-title>Biofilm formation capacity of <italic>Pseudomonas aeruginosa</italic> is significantly enhanced by sub-inhibitory concentrations of Tomatidine</article-title><source>Gene Rep</source><year>2022</year><volume>27</volume><fpage>101570</fpage><pub-id pub-id-type="doi">10.1016/j.genrep.2022.101570</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Noori HG, Tadjrobehkar O, Moazamian E (2022) Biofilm formation capacity of <italic>Pseudomonas aeruginosa</italic> is significantly enhanced by sub-inhibitory concentrations of Tomatidine. Gene Rep 27:101570. 10.1016/j.genrep.2022.101570</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Mirani</surname><given-names>ZA</given-names></name><name><surname>Fatima</surname><given-names>A</given-names></name><name><surname>Urooj</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>M</given-names></name><name><surname>Khan</surname><given-names>MN</given-names></name><name><surname>Abbas</surname><given-names>T</given-names></name></person-group><article-title>Relationship of cell surface hydrophobicity with biofilm formation and growth rate: a study on <italic>Pseudomonas aeruginosa</italic>, <italic>Staphylococcus aureus</italic>, and <italic>Escherichia coli</italic></article-title><source>Iran J Basic Med Sci</source><year>2018</year><volume>21</volume><fpage>760</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.22038/IJBMS.2018.28525.6917</pub-id><pub-id pub-id-type="pmid">30140417</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Mirani ZA, Fatima A, Urooj S, Aziz M, Khan MN, Abbas T (2018) Relationship of cell surface hydrophobicity with biofilm formation and growth rate: a study on <italic>Pseudomonas aeruginosa</italic>, <italic>Staphylococcus aureus</italic>, and <italic>Escherichia coli</italic>. Iran J Basic Med Sci 21:760&#x02013;769. 10.22038/IJBMS.2018.28525.6917<pub-id pub-id-type="pmid">30140417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Yousefpour</surname><given-names>Z</given-names></name><name><surname>Davarzani</surname><given-names>F</given-names></name><name><surname>Owlia</surname><given-names>P</given-names></name></person-group><article-title>Evaluating of the EFFECTS of sub-MIC concentrations of gentamicin on biofilm formation in clinical isolates of <italic>Pseudomonas aeruginosa</italic></article-title><source>Iran J Pathol</source><year>2021</year><volume>16</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.30699/IJP.20201.524220.2584</pub-id><pub-id pub-id-type="pmid">34567189</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Yousefpour Z, Davarzani F, Owlia P (2021) Evaluating of the EFFECTS of sub-MIC concentrations of gentamicin on biofilm formation in clinical isolates of <italic>Pseudomonas aeruginosa</italic>. Iran J Pathol 16:403&#x02013;410. 10.30699/IJP.20201.524220.2584<pub-id pub-id-type="pmid">34567189</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>S</given-names></name><name><surname>O&#x02019;Grady</surname><given-names>MC</given-names></name><name><surname>Corcoran</surname><given-names>GD</given-names></name><name><surname>Finn</surname><given-names>K</given-names></name><name><surname>Lucey</surname><given-names>B</given-names></name></person-group><article-title>Effect of sub-inhibitory concentrations of nitrofurantoin, ciprofloxacin, and trimethoprim on in vitro biofilm formation in uropathogenic <italic>Escherichia coli</italic> (UPEC)</article-title><source>Med Sci</source><year>2023</year><volume>11</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.3390/medsci11010001</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Whelan S, O&#x02019;Grady MC, Corcoran GD, Finn K, Lucey B (2023) Effect of sub-inhibitory concentrations of nitrofurantoin, ciprofloxacin, and trimethoprim on in vitro biofilm formation in uropathogenic <italic>Escherichia coli</italic> (UPEC). Med Sci 11:1. 10.3390/medsci11010001</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Abinaya</surname><given-names>M</given-names></name><name><surname>Gayathri</surname><given-names>M</given-names></name></person-group><article-title>Inhibition of biofilm formation, quorum sensing activity and molecular docking study of isolated 3, 5, 7-trihydroxyflavone from <italic>Alstonia scholaris</italic> leaf against <italic>P. aeruginosa</italic></article-title><source>Bioorg Chem</source><year>2019</year><volume>87</volume><fpage>291</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/j.bioorg.2019.03.050</pub-id><pub-id pub-id-type="pmid">30913464</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Abinaya M, Gayathri M (2019) Inhibition of biofilm formation, quorum sensing activity and molecular docking study of isolated 3, 5, 7-trihydroxyflavone from <italic>Alstonia scholaris</italic> leaf against <italic>P. aeruginosa</italic>. Bioorg Chem 87:291&#x02013;301. 10.1016/j.bioorg.2019.03.050<pub-id pub-id-type="pmid">30913464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Farniya</surname><given-names>F</given-names></name><name><surname>Jamalli</surname><given-names>A</given-names></name><name><surname>Dadgar</surname><given-names>T</given-names></name><name><surname>Akhter</surname><given-names>Y</given-names></name></person-group><article-title>Physicochemical surface characteristics in different pathogenic bacteria</article-title><source>Cogent Biol</source><year>2019</year><volume>5</volume><fpage>1638572</fpage><pub-id pub-id-type="doi">10.1080/23312025.2019.1638572</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Farniya F, Jamalli A, Dadgar T, Akhter Y (2019) Physicochemical surface characteristics in different pathogenic bacteria. Cogent Biol 5:1638572. 10.1080/23312025.2019.1638572</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Masak</surname><given-names>J</given-names></name><name><surname>Cejkova</surname><given-names>A</given-names></name><name><surname>Schreiberova</surname><given-names>O</given-names></name><name><surname>Rezanka</surname><given-names>T</given-names></name></person-group><article-title>Pseudomonas biofilms: possibilities of their control</article-title><source>FEMS Microbiol Ecol</source><year>2014</year><volume>89</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1111/1574-6941.12344</pub-id><pub-id pub-id-type="pmid">24754832</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Masak J, Cejkova A, Schreiberova O, Rezanka T (2014) Pseudomonas biofilms: possibilities of their control. FEMS Microbiol Ecol 89:1&#x02013;14. 10.1111/1574-6941.12344<pub-id pub-id-type="pmid">24754832</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Krasowska</surname><given-names>A</given-names></name><name><surname>Sigler</surname><given-names>K</given-names></name></person-group><article-title>How microorganisms use hydrophobicity and what does this mean for human needs?</article-title><source>Front Cell Infect Microbiol</source><year>2014</year><volume>4</volume><fpage>112</fpage><pub-id pub-id-type="doi">10.3389/fcimb.2014.00112</pub-id><pub-id pub-id-type="pmid">25191645</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Krasowska A, Sigler K (2014) How microorganisms use hydrophobicity and what does this mean for human needs? Front Cell Infect Microbiol 4:112. 10.3389/fcimb.2014.00112<pub-id pub-id-type="pmid">25191645</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>M</given-names></name></person-group><article-title>Microbial adhesion to hydrocarbons: twenty-five years of doing MATH</article-title><source>FEMS Microbiol Lett</source><year>2006</year><volume>262</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2006.00291.x</pub-id><pub-id pub-id-type="pmid">16923066</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Rosenberg M (2006) Microbial adhesion to hydrocarbons: twenty-five years of doing MATH. FEMS Microbiol Lett 262:129&#x02013;134. 10.1111/j.1574-6968.2006.00291.x<pub-id pub-id-type="pmid">16923066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Siddhardha</surname><given-names>B</given-names></name><name><surname>Pandey</surname><given-names>U</given-names></name><name><surname>Kaviyarasu</surname><given-names>K</given-names></name><name><surname>Pala</surname><given-names>R</given-names></name><name><surname>Syed</surname><given-names>A</given-names></name><name><surname>Bahkali</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Chrysin-loaded chitosan nanoparticles potentiates antibiofilm activity against <italic>Staphylococcus aureus</italic></article-title><source>Pathogens</source><year>2020</year><volume>9</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.3390/pathogens9020115</pub-id><pub-id pub-id-type="pmid">32059467</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Siddhardha B, Pandey U, Kaviyarasu K, Pala R, Syed A, Bahkali AH et al (2020) Chrysin-loaded chitosan nanoparticles potentiates antibiofilm activity against <italic>Staphylococcus aureus</italic>. Pathogens 9:115. 10.3390/pathogens9020115<pub-id pub-id-type="pmid">32059467</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>HA</given-names></name><name><surname>Shaldam</surname><given-names>MA</given-names></name><name><surname>Eldamasi</surname><given-names>D</given-names></name></person-group><article-title>Curtailing QUORUM SENSIng in <italic>Pseudomonas aeruginosa</italic> by sitagliptin</article-title><source>Curr Microbiol</source><year>2020</year><volume>77</volume><fpage>1051</fpage><lpage>1060</lpage><pub-id pub-id-type="doi">10.1007/s00284-020-01909-4</pub-id><pub-id pub-id-type="pmid">32020464</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Abbas HA, Shaldam MA, Eldamasi D (2020) Curtailing QUORUM SENSIng in <italic>Pseudomonas aeruginosa</italic> by sitagliptin. Curr Microbiol 77:1051&#x02013;1060. 10.1007/s00284-020-01909-4<pub-id pub-id-type="pmid">32020464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Olivares</surname><given-names>E</given-names></name><name><surname>Badel-Berchoux</surname><given-names>S</given-names></name><name><surname>Provot</surname><given-names>C</given-names></name><name><surname>Prevost</surname><given-names>G</given-names></name><name><surname>Bernardi</surname><given-names>T</given-names></name><name><surname>Jehl</surname><given-names>F</given-names></name></person-group><article-title>Clinical impact of antibiotics for the treatment of <italic>Pseudomonas aeruginosa</italic> biofilm infections</article-title><source>Front Microbiol</source><year>2019</year><volume>10</volume><fpage>2894</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.02894</pub-id><pub-id pub-id-type="pmid">31998248</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Olivares E, Badel-Berchoux S, Provot C, Prevost G, Bernardi T, Jehl F (2019) Clinical impact of antibiotics for the treatment of <italic>Pseudomonas aeruginosa</italic> biofilm infections. Front Microbiol 10:2894. 10.3389/fmicb.2019.02894<pub-id pub-id-type="pmid">31998248</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Grossman</surname><given-names>S</given-names></name><name><surname>Soukarieh</surname><given-names>F</given-names></name><name><surname>Richardson</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Mashabi</surname><given-names>A</given-names></name><name><surname>Emsley</surname><given-names>J</given-names></name><etal/></person-group><article-title>Novel quinazolinone inhibitors of the <italic>Pseudomonas aeruginosa</italic> quorum sensing transcriptional regulator PqsR</article-title><source>Euro J Med Chem</source><year>2020</year><volume>208</volume><fpage>112778</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112778</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Grossman S, Soukarieh F, Richardson W, Liu R, Mashabi A, Emsley J et al (2020) Novel quinazolinone inhibitors of the <italic>Pseudomonas aeruginosa</italic> quorum sensing transcriptional regulator PqsR. Euro J Med Chem 208:112778. 10.1016/j.ejmech.2020.112778</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Monforte</surname><given-names>AM</given-names></name><name><surname>De Luca</surname><given-names>L</given-names></name><name><surname>Buemi</surname><given-names>MR</given-names></name><name><surname>Agharbaoui</surname><given-names>FE</given-names></name><name><surname>Pannecouque</surname><given-names>C</given-names></name><name><surname>Ferro</surname><given-names>S</given-names></name></person-group><article-title>Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains</article-title><source>Bioorg Med Chem</source><year>2018</year><volume>26</volume><fpage>661</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2017.12.033</pub-id><pub-id pub-id-type="pmid">29291935</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Monforte AM, De Luca L, Buemi MR, Agharbaoui FE, Pannecouque C, Ferro S (2018) Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem 26:661&#x02013;674. 10.1016/j.bmc.2017.12.033<pub-id pub-id-type="pmid">29291935</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghabrial</surname><given-names>SS</given-names></name><name><surname>Gaber</surname><given-names>HM</given-names></name></person-group><article-title>Dipolar cycloaddition reactions with quinazolinones: a new route for the synthesis of several annelated pyrrolo- and pyridazinoquinazoline derivatives</article-title><source>Molecules</source><year>2003</year><volume>8</volume><fpage>401</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.3390/80500401</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Ghabrial SS, Gaber HM (2003) Dipolar cycloaddition reactions with quinazolinones: a new route for the synthesis of several annelated pyrrolo- and pyridazinoquinazoline derivatives. Molecules 8:401&#x02013;410. 10.3390/80500401</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Balouiri</surname><given-names>M</given-names></name><name><surname>Sadiki</surname><given-names>M</given-names></name><name><surname>Ibnsouda</surname><given-names>SK</given-names></name></person-group><article-title>Methods for in vitro evaluating antimicrobial activity: a review</article-title><source>J Pharm Anal</source><year>2016</year><volume>6</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.jpha.2015.11.005</pub-id><pub-id pub-id-type="pmid">29403965</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Balouiri M, Sadiki M, Ibnsouda SK (2016) Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal 6:71&#x02013;79. 10.1016/j.jpha.2015.11.005<pub-id pub-id-type="pmid">29403965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Heatley</surname><given-names>NG</given-names></name></person-group><article-title>A method for the assay of penicillin</article-title><source>Biochem J</source><year>1944</year><volume>38</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1042/bj0380061</pub-id><pub-id pub-id-type="pmid">16747749</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Heatley NG (1944) A method for the assay of penicillin. Biochem J 38:61&#x02013;65. 10.1042/bj0380061<pub-id pub-id-type="pmid">16747749</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Mosmann</surname><given-names>T</given-names></name></person-group><article-title>Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays</article-title><source>J Immunol Methods</source><year>1983</year><volume>65</volume><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(83)90303-4</pub-id><pub-id pub-id-type="pmid">6606682</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55&#x02013;63. 10.1016/0022-1759(83)90303-4<pub-id pub-id-type="pmid">6606682</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="book"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>SS</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Nielsen</surname><given-names>SS</given-names></name></person-group><article-title>Total carbohydrate by phenol-sulfuric acid method</article-title><source>Food Analysis laboratory manual</source><year>2017</year><publisher-loc>Cham</publisher-loc><publisher-name>Springer</publisher-name><fpage>137</fpage><lpage>141</lpage></element-citation><mixed-citation id="mc-CR72" publication-type="book">Nielsen SS (2017) Total carbohydrate by phenol-sulfuric acid method. In: Nielsen SS (ed) Food Analysis laboratory manual. Springer, Cham, pp 137&#x02013;141</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Qiao</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Bai</surname><given-names>Q</given-names></name><name><surname>Walcott</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name></person-group><article-title><italic>ntrC</italic> contributes to nitrogen utilization, stress tolerance, and virulence in <italic>Acidovorax citrulli</italic></article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><fpage>767</fpage><pub-id pub-id-type="doi">10.3390/microorganisms11030767</pub-id><pub-id pub-id-type="pmid">36985340</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Liu D, Zhao M, Qiao P, Li Z, Chen G, Guan W, Bai Q, Walcott R, Yang Y, Zhao T (2023) <italic>ntrC</italic> contributes to nitrogen utilization, stress tolerance, and virulence in <italic>Acidovorax citrulli</italic>. Microorganisms 11:767. 10.3390/microorganisms11030767<pub-id pub-id-type="pmid">36985340</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>